

**ADIMMUNE CORPORATION AND  
SUBSIDIARIES**  
**CONSOLIDATED FINANCIAL STATEMENTS AND**  
**INDEPENDENT AUDITORS' REVIEW REPORT**  
**MARCH 31, 2025 AND 2024**

---

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.

## INDEPENDENT AUDITORS' REVIEW REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of Adimmune Corporation

### ***Introduction***

We have reviewed the accompanying consolidated balance sheets of Adimmune Corporation and subsidiaries (the “Group”) as at March 31, 2025 and 2024, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the three-month periods then ended, and notes to the consolidated financial statements, including a summary of material accounting policies. Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” that came into effect as endorsed by the Financial Supervisory Commission. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

### ***Scope of review***

We conducted our reviews in accordance with the Standard on Review Engagements 2410, “Review of Financial Information Performed by the Independent Auditor of the Entity” of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

## ***Conclusion***

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as at March 31, 2025 and 2024, and of its consolidated financial performance and its consolidated cash flows for the three-month periods then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” that came into effect as endorsed by the Financial Supervisory Commission.

---

Hsu, Chien-Yeh

Lai, Chih-Wei

For and on behalf of PricewaterhouseCoopers, Taiwan

May 13, 2025

---

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

ADIMMUNE CORPORATION AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEETS  
MARCH 31, 2025, DECEMBER 31, 2024 AND MARCH 31, 2024  
(Expressed in thousands of New Taiwan dollars)

	Assets	Notes	March 31, 2025		December 31, 2024		March 31, 2024	
			AMOUNT	%	AMOUNT	%	AMOUNT	%
<b>Current assets</b>								
1100	Cash and cash equivalents	6(1)	\$ 2,028,889	24	\$ 2,344,620	28	\$ 2,979,145	32
1136	Financial assets at amortised cost - 6(2) and 8							
	current		127,507	2	127,507	2	27,507	-
1150	Notes receivable, net	6(3)	5,213	-	-	-	-	-
1170	Accounts receivable, net	6(3)	179,557	2	187,806	2	402,032	4
130X	Inventories	6(4)	688,033	8	627,993	7	688,889	8
1410	Prepayments	6(5)	223,552	3	240,046	3	279,739	3
1470	Other current assets	8	94,605	1	82,032	1	98,196	1
11XX	<b>Current Assets</b>		<u>3,347,356</u>	<u>40</u>	<u>3,610,004</u>	<u>43</u>	<u>4,475,508</u>	<u>48</u>
<b>Non-current assets</b>								
1517	Financial assets at fair value	6(6)						
	through other comprehensive							
	income - non-current		101,301	1	109,663	1	118,489	1
1535	Financial assets at amortised cost - 6(2) and 8							
	non-current		88,917	1	5,017	-	87,959	1
1560	Non-current contract assets	6(19)	334,933	4	334,933	4	334,933	4
1600	Property, plant and equipment	6(7) and 8	3,796,465	46	3,742,188	44	3,536,198	38
1755	Right-of-use assets		79,115	1	75,465	1	68,067	1
1760	Investment property, net		23,239	-	23,239	-	23,252	-
1780	Intangible assets	6(8)	42,348	1	47,860	-	65,188	1
1840	Deferred income tax assets	6(25)	227,415	3	227,415	3	227,602	2
1900	Other non-current assets	6(9) and 8	288,921	3	305,669	4	419,979	4
15XX	<b>Non-current assets</b>		<u>4,982,654</u>	<u>60</u>	<u>4,871,449</u>	<u>57</u>	<u>4,881,667</u>	<u>52</u>
1XXX	<b>Total assets</b>		<u>\$ 8,330,010</u>	<u>100</u>	<u>\$ 8,481,453</u>	<u>100</u>	<u>\$ 9,357,175</u>	<u>100</u>

(Continued)

**ADIMMUNE CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED BALANCE SHEETS**  
**MARCH 31, 2025, DECEMBER 31, 2024 AND MARCH 31, 2024**  
(Expressed in thousands of New Taiwan dollars)

	Liabilities and Equity	Notes	March 31, 2025		December 31, 2024		March 31, 2024	
			AMOUNT	%	AMOUNT	%	AMOUNT	%
<b>Current liabilities</b>								
2100	Short-term borrowings	6(10)	\$ 400,000	5	\$ 500,000	6	\$ 540,000	6
2130	Current contract liabilities	6(19)	68,665	1	9,394	-	93,805	1
2150	Notes payable		7,381	-	60	-	2,788	-
2170	Accounts payable		42,659	1	31,190	-	68,308	1
2200	Other payables	6(11)	168,223	2	254,993	3	203,167	2
2250	Provisions for liabilities - current	6(15)	17,248	-	17,248	-	-	-
2280	Current lease liabilities		22,598	-	19,017	-	16,707	-
2320	Long-term liabilities, current portion	6(12)	523,171	6	320,044	4	669,938	7
2399	Other current liabilities, others	6(3)	10,413	-	9,364	-	247,284	3
21XX	<b>Current Liabilities</b>		<u>1,260,358</u>	<u>15</u>	<u>1,161,310</u>	<u>13</u>	<u>1,841,997</u>	<u>20</u>
<b>Non-current liabilities</b>								
2540	Long-term borrowings	6(12)	1,718,070	21	1,705,285	20	1,868,747	20
2580	Non-current lease liabilities		49,961	-	52,329	1	46,663	-
2600	Other non-current liabilities	6(13)	1,422	-	838	-	1,858	-
25XX	<b>Non-current liabilities</b>		<u>1,769,453</u>	<u>21</u>	<u>1,758,452</u>	<u>21</u>	<u>1,917,268</u>	<u>20</u>
2XXX	<b>Total Liabilities</b>		<u>3,029,811</u>	<u>36</u>	<u>2,919,762</u>	<u>34</u>	<u>3,759,265</u>	<u>40</u>
<b>Equity</b>								
	Share capital	6(16)						
3110	Share capital - common stock		4,295,078	52	4,295,078	51	4,295,078	46
	Capital surplus	6(17)						
3200	Capital surplus		829,498	10	829,498	10	835,406	9
	Retained earnings	6(18)						
3310	Legal reserve		145,781	2	145,781	2	145,781	1
3350	Unappropriated retained earnings (accumulated deficit)		( 17,844)	-	205,409	2	267,860	3
	Other equity interest							
3400	Other equity interest		41,554	-	49,493	1	53,094	1
3500	Treasury shares	6(16)	( 292,538)	( 4)	( 292,538)	( 4)	( 292,538)	( 3)
31XX	<b>Equity attributable to owners of the parent</b>		<u>5,001,529</u>	<u>60</u>	<u>5,232,721</u>	<u>62</u>	<u>5,304,681</u>	<u>57</u>
36XX	Non-controlling interest		<u>298,670</u>	<u>4</u>	<u>328,970</u>	<u>4</u>	<u>293,229</u>	<u>3</u>
3XXX	<b>Total equity</b>		<u>5,300,199</u>	<u>64</u>	<u>5,561,691</u>	<u>66</u>	<u>5,597,910</u>	<u>60</u>
	Significant contingent liabilities and unrecognised contract commitments	9						
3X2X	<b>Total liabilities and equity</b>		<u>\$ 8,330,010</u>	<u>100</u>	<u>\$ 8,481,453</u>	<u>100</u>	<u>\$ 9,357,175</u>	<u>100</u>

The accompanying notes are an integral part of these consolidated financial statements.

**ADIMMUNE CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**  
**THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024**  
(Expressed in thousands of New Taiwan dollars, except loss per share amount)

Items	Notes	Three-month periods ended March 31			
		2025		2024	
		AMOUNT	%	AMOUNT	%
4000 Sales revenue	6(19)	\$ 72,104	100	\$ 43,878	100
5000 Operating costs	6(4)(8)(23)	(193,388)	(268)	(114,191)	(260)
5900 Net operating margin		(121,284)	(168)	(70,313)	(160)
Operating expenses	6(8)(23)				
6100 Selling expenses		(15,052)	(21)	(7,918)	(18)
6200 General and administrative expenses		(75,234)	(104)	(72,677)	(166)
6300 Research and development expenses		(53,317)	(74)	(44,469)	(101)
6000 Total operating expenses		(143,603)	(199)	(125,064)	(285)
6900 Operating loss		(264,887)	(367)	(195,377)	(445)
Non-operating income and expenses					
7100 Interest income	6(20)	3,241	5	1,470	3
7010 Other income	6(21)	789	1	1,934	5
7020 Other gains and losses	6(22)	10,986	15	1,360	3
7050 Finance costs	6(24)	(5,517)	(8)	(10,099)	(23)
7000 Total non-operating revenue and expenses		9,499	13	(5,335)	(12)
7900 <b>Loss before income tax</b>		(255,388)	(354)	(200,712)	(457)
7950 Income tax expense	6(25)	-	-	-	-
8200 <b>Loss for the year</b>		<u>(\$ 255,388)</u>	<u>(354)</u>	<u>(\$ 200,712)</u>	<u>(457)</u>
<b>Other comprehensive income</b>					
<b>Components of other comprehensive income that will not be reclassified to profit or loss</b>					
8316 Unrealized loss on valuation of equity instruments at fair value through profit or loss	6(6)				
		<u>(\$ 8,362)</u>	<u>(12)</u>	<u>\$ 12,629</u>	<u>29</u>
8310 Components of other comprehensive loss that will be reclassified to profit or loss					
		<u>(8,362)</u>	<u>(12)</u>	<u>12,629</u>	<u>29</u>
<b>Components of other comprehensive income that will be reclassified to profit or loss</b>					
8361 Exchange differences on translation		1,528	2	5,427	12
8360 Components of other comprehensive income that will be reclassified to profit or loss		1,528	2	5,427	12
8300 <b>Other comprehensive (loss) income for the year</b>		<u>(\$ 6,834)</u>	<u>(10)</u>	<u>\$ 18,056</u>	<u>41</u>
8500 <b>Total comprehensive loss for the year</b>		<u>(\$ 262,222)</u>	<u>(364)</u>	<u>(\$ 182,656)</u>	<u>(416)</u>
Loss, attributable to:					
8610 Owners of the parent		<u>(\$ 223,253)</u>	<u>(310)</u>	<u>(\$ 183,970)</u>	<u>(419)</u>
8620 Non-controlling interest		<u>(32,135)</u>	<u>(44)</u>	<u>(16,742)</u>	<u>(38)</u>
8720 Total		<u>(\$ 255,388)</u>	<u>(354)</u>	<u>(\$ 200,712)</u>	<u>(457)</u>
Comprehensive loss attributable to:					
8710 Owners of the parent		<u>(\$ 231,192)</u>	<u>(321)</u>	<u>(\$ 169,819)</u>	<u>(387)</u>
8720 Non-controlling interest		<u>(31,030)</u>	<u>(43)</u>	<u>(12,837)</u>	<u>(29)</u>
8950 Total		<u>(\$ 262,222)</u>	<u>(364)</u>	<u>(\$ 182,656)</u>	<u>(416)</u>
Basic loss per share	6(26)				
9750 Total basic loss per share		<u>(\$ 0.53)</u>	<u>(\$ 0.44)</u>		
Diluted loss per share	6(26)				
9850 Diluted loss per share		<u>(\$ 0.53)</u>	<u>(\$ 0.44)</u>		

The accompanying notes are an integral part of these consolidated financial statements.

**ADIMMUNE CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY**  
**THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024**  
(Expressed in thousands of New Taiwan dollars)

Notes	Equity attributable to owners of the parent												Non-controlling interest	Total equity		
	Capital surplus			Retained earnings			Other equity interest			Treasury shares	Total					
	Share capital - common stock	Additional paid-in capital	Difference between consideration and carrying amount of subsidiaries acquired or disposed	Employee stock warrants	Legal reserve	Unappropriated retained earnings (accumulated deficit)	Exchange differences on translation of foreign financial statements	Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income								
<b>2024</b>																
Balance at January 1, 2024	\$ 4,295,078	\$ 817,861	\$ -	\$ 17,545	\$ 145,781	\$ 451,830	(\$ 1,367)	\$ 40,310	(\$ 292,538)	\$ 5,474,500	\$ 303,066	\$ 5,777,566				
Net loss for 2024	-	-	-	-	-	-	(183,970)	-	-	-	(183,970)	(16,742)	(200,712)			
Other comprehensive income for the period	6(6)	-	-	-	-	-	-	1,522	12,629	-	14,151	3,905	18,056			
Total comprehensive income (loss)		-	-	-	-	-	(183,970)	1,522	12,629	-	(169,819)	(12,837)	(182,656)			
Share-based payments	6(14)	-	-	-	-	-	-	-	-	-	-	3,000	3,000			
Balance at March 31, 2024	\$ 4,295,078	\$ 817,861	\$ -	\$ 17,545	\$ 145,781	\$ 267,860	\$ 155	\$ 52,939	(\$ 292,538)	\$ 5,304,681	\$ 293,229	\$ 5,597,910				
<b>2025</b>																
Balance at January 1, 2025	\$ 4,295,078	\$ 817,861	\$ 11,637	\$ -	\$ 145,781	\$ 205,409	\$ 959	\$ 48,534	(\$ 292,538)	\$ 5,232,721	\$ 328,970	\$ 5,561,691				
Net loss for 2025	-	-	-	-	-	-	(223,253)	-	-	-	(223,253)	(32,135)	(255,388)			
Other comprehensive income (loss) for the period	6(6)	-	-	-	-	-	-	423	(8,362)	-	(7,939)	1,105	(6,834)			
Total comprehensive income (loss)		-	-	-	-	-	(223,253)	423	(8,362)	-	(231,192)	(31,030)	(262,222)			
Share-based payments	6(14)	-	-	-	-	-	-	-	-	-	-	730	730			
Balance at March 31, 2025	\$ 4,295,078	\$ 817,861	\$ 11,637	\$ -	\$ 145,781	(\$ 17,844)	\$ 1,382	\$ 40,172	(\$ 292,538)	\$ 5,001,529	\$ 298,670	\$ 5,300,199				

The accompanying notes are an integral part of these consolidated financial statements.

**ADIMMUNE CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024**  
(Expressed in thousands of New Taiwan dollars)

	Notes	Three-month periods ended March 31	
		2025	2024
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Loss before tax		(\$ 255,388 )	(\$ 200,712 )
Adjustments			
Adjustments to reconcile profit (loss)			
Depreciation (including right-of-use assets)	6(23)	46,828	49,909
Amortization	6(23)	5,988	6,184
Reversal of expected credit losses	12(2)	( 4 )	( 160 )
Gain from lease modification	6(22)	- ( 1 )	1 ( 1 )
Interest expense	6(24)	5,517	10,099
Interest income	6(20)	( 3,241 )	( 1,470 )
Share-based payments	6(14)	2,865	7,681
Changes in operating assets and liabilities			
Changes in operating assets			
Notes receivable, net		( 5,213 )	15
Accounts receivable, net		8,253	906,204
Inventories		( 60,040 )	( 162,483 )
Prepayments		16,494	2,322
Other current assets		( 12,111 )	( 489 )
Changes in operating liabilities			
Contract liabilities-current		59,271	71,993
Notes payable		7,321	2,788
Accounts payable, net		11,469	25,957
Other payables		( 38,453 )	( 64,140 )
Other current liabilities		1,049	3,171
Net defined benefit liabilities - non-current		( 81 )	( 81 )
Other non-current liabilities		5	4
Cash (outflow) inflow generated from operations		( 209,471 )	656,791
Interest paid		( 5,216 )	( 10,034 )
Interest received		2,769	1,505
Net cash flows (used in) from operating activities		( 211,918 )	648,262

(Continued)

**ADIMMUNE CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024**  
(Expressed in thousands of New Taiwan dollars)

	Notes	Three-month periods ended March 31	
		2025	2024
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Increase in financial assets at amortised cost- non-current		(\$ 83,900 )	(\$ 83,900 )
Acquisition of property, plant and equipment	6(28)	( 108,772 )	( 20,213 )
Actual interest paid capitalized	6(7)(28)	( 10,105 )	( 8,079 )
Increase in prepaid equipment	6(28)	( 10,114 )	( 13,703 )
Increase in refundable deposits		( 140 )	( 223 )
Acquisition of intangible assets	6(8)	( 250 )	( 680 )
Net cash flows used in investing activities		( 213,281 )	( 126,798 )
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Repayment from short-term borrowings	6(29)	( 100,000 )	-
Proceeds from long-term borrowings	6(29)	216,820	-
Repayment from long-term borrowings	6(29)	( 908 )	( 530 )
Repayment of principal portion of lease liabilities	6(29)	( 7,972 )	( 4,717 )
Net cash flows from (used in) financing activities		107,940	( 5,247 )
Effect of exchange rate changes on cash and cash equivalents		1,528	5,427
Net (decrease) increase in cash and cash equivalents		( 315,731 )	521,644
Cash and cash equivalents at beginning of period	6(1)	2,344,620	2,457,501
Cash and cash equivalents at end of period	6(1)	\$ 2,028,889	\$ 2,979,145

The accompanying notes are an integral part of these consolidated financial statements.

**ADIMMUNE CORPORATION AND SUBSIDIARIES**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024**

(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

**1. HISTORY AND ORGANISATION**

Adimmune Co., Ltd. (the “Company”) was incorporated as a company limited by shares under the provisions of the Company Act of the Republic of China (R.O.C.) in 1965. The Company and its subsidiary (collectively referred herein as the “Group”) are primarily engaged in the research and development, processing, manufacturing and trading of serum, vaccines, testing reagents, biologicals and other bacterial fluids; and the processing, manufacturing and trading of western medicines, animal medicines, chemicals and feed additives, etc. The Company’s shares were approved to be traded in the Taiwan Stock Exchange starting from May 3, 2012.

**2. THE DATE OF AUTHORISATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL STATEMENTS AND PROCEDURES FOR AUTHORISATION**

These consolidated financial statements were reported to the Board of Directors on May 13, 2025.

**3. APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS**

**(1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS®”) Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission (“FSC”)**

New standards, interpretations and amendments endorsed by the FSC and became effective from 2025 are as follows:

New Standards, Interpretations and Amendments	Effective date by International Accounting Standards Board
Amendments to IAS 21, ‘Lack of exchangeability’	January 1, 2025

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(2) Effect of new issuances of or amendments to IFRS Accounting Standards as endorsed by the FSC but not yet adopted by the Group

New standards, interpretations and amendments endorsed by the FSC effective from 2025 are as follows:

New Standards, Interpretations and Amendments	Effective date by International Accounting Standards Board
Specific provisions of Amendments to IFRS 9 and IFRS 7, 'Amendments to the classification and measurement of financial instruments'	January 1, 2026

The above standards and interpretations have no significant impact to the Group's financial condition and financial performance based on the Group's assessment.

(3) IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

New standards, interpretations and amendments issued by IASB but not yet included in the IFRSs as endorsed by the FSC are as follows:

New Standards, Interpretations and Amendments	Effective date by International Accounting Standards Board
Specific provisions of Amendments to IFRS 9 and IFRS 7, 'Amendments to the classification and measurement of financial instruments'	January 1, 2026
Amendments to IFRS 9 and IFRS 7, 'Contracts referencing nature-dependent electricity'	January 1, 2026
Amendments to IFRS 10 and IAS 28, 'Sale or contribution of assets between an investor and its associate or joint venture'	To be determined by International Accounting Standards Board
IFRS 17, 'Insurance contracts'	January 1, 2023
Amendments to IFRS 17, 'Insurance contracts'	January 1, 2023
Amendment to IFRS 17, 'Initial application of IFRS 17 and IFRS 9 – comparative information'	January 1, 2023
IFRS 18, 'Presentation and disclosure in financial statements'	January 1, 2027
IFRS 19, 'Subsidiaries without public accountability: disclosures'	January 1, 2027
Annual Improvements to IFRS Accounting Standards—Volume 11	January 1, 2026

Except for the following, the above standards and interpretations have no significant impact to the Group's financial condition and financial performance based on the Group's assessment:

IFRS 18, 'Presentation and disclosure in financial statements' replaces IAS 1. The standard introduces a defined structure of the statement of profit or loss, disclosure requirements related to management-defined performance measures, and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes.

#### **4. Summary of Material Accounting Policies**

The principal accounting policies adopted are consistent with Note 4 in the consolidated financial statements for the year ended December 31, 2024, except for the compliance statement, basis of preparation, basis of consolidation and additional policies as set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

##### **(1) Compliance statement**

- A. The consolidated financial statements of the Group have been prepared in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” and the International Accounting Standard 34, ‘Interim financial reporting’ that came into effect as endorsed by the FSC.
- B. These consolidated financial statements are to be read in conjunction with the consolidated financial statements for the year ended December 31, 2024.

##### **(2) Basis of preparation**

- A. Except for the following items, these consolidated financial statements have been prepared under the historical cost convention:
  - (a) Financial assets at fair value through profit.
  - (b) Defined benefit liabilities recognised based on the net amount of pension fund assets less present value of defined benefit obligation.
- B. The preparation of financial statements in conformity with International Financial Reporting Standards, International Accounting Standards, IFRIC® Interpretations, and SIC® Interpretations that came into effect as endorsed by the FSC (collectively referred herein as the “IFRSs”) requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 5.

##### **(3) Basis of consolidation**

- A. Basis for preparation of consolidated financial statements:

Basis for preparation of these consolidated financial statements is the same as that for the preparation of the consolidated financial statements as of and for the year ended December 31, 2024.

B. Subsidiary included in the consolidated financial statements:

Name of investor	Name of subsidiary	Main business activities	Ownership (%)			Footnote
			March 31, 2025	December 31, 2024	March 31, 2024	
Adimmune Corporation	Enimmune Corporation	Biotechnology industry	50.26	50.26	51	Notes 2, 3
Adimmune Corporation	Global Commonwealth Life Science (Holdings) Limited	General investment	100	100	100	
Adimmune Corporation	ADIMMUNE B.V.	General investment	100	100	100	
Adimmune Corporation	Eggs Corporation	Animal husbandry	100	100	100	
Adimmune Corporation	Adimmune Co., Ltd. Nanjing, China	Trading	100	100	100	
Eggs Corporation	Animmune Corporation	Biotechnology industry	51.22	51.22	51.22	
Enimmune Corporation	ENIMMUNE-RMT BIOTECH PTE. LTD.	Biotechnology industry	55	55	55	Note 1

Note:

1. After the cooperation between the Group's subsidiary, Enimmune Corporation ("Enimmune"), and Reliance Medical Technology ("RMT company"), there were differences in the operation plan of Enimmune-RMT Biotech Pte. Ltd. ("EB Company"). After considering the development requirement in the Southeast Asian market and at the same time safeguarding the shareholders' rights of Enimmune, the Board of Directors of Enimmune during their meeting on February 24, 2023 resolved that EB company carry out a capital reduction and shares retirement. The capital reduction amounted to USD 4.5 million with a capital reduction ratio of 45%, and Enimmune holds 100% of EB company's shares after the capital reduction. The most likely outcome of the agreement assessed by the Group is provided in Note 6(15). However, the details of the capital reduction were still under negotiation by both parties as of May 13, 2025.
2. On March 12, 2023, the Board of Directors of the subsidiary, Enimmune Corporation, during its meeting resolved to increase its capital by issuing 6,250 thousand common shares with a par value of \$10 (in dollars) per share totalling NT\$62,500 thousand. Considering the overall business benefits, the Group participated in the capital increase by purchasing 2,696 thousand shares at a price of NT\$32 (in dollars) per share totalling \$86,294 thousand. However, the Group did not acquire shares proportionally to its interest. As a result, the Group decreased its interest by 0.68% to 50.32% after the capital increase. The abovementioned capital increase was registered with the regulatory authority on July 5, 2024.

3. On August 17, 2022, the board of directors of Enimmune Corporation, a subsidiary of the Group, resolved to issue employee stock options (please refer to Note 6(14) for details). Upon exercise of the stock options, November 11, 2024 was set as the record date for the issuance of new shares. As a result of this issuance, the Group's ownership interest in ENIMMUNE CORPORATION decreased by 0.06%, bringing the Group's shareholding ratio to 50.26%. The change in registration for the new share issuance was completed with the competent authority on December 2, 2024.

C. Subsidiaries not included in the consolidated financial statements: None.

D. Adjustments for subsidiaries with different balance sheet dates: None.

E. Significant restrictions: None.

F. Subsidiaries that have non-controlling interests that are material to the Group: None.

**(4) Classification of current and non-current items**

A. Assets that meet one of the following criteria are classified as current assets; otherwise they are classified as non-current assets:

- (a) Assets that are expected to be realised, or are intended to be sold or consumed in the normal operating cycle;
- (b) Assets that are held primarily for the purpose of trading;
- (c) Assets that are expected to be realised within twelve months after the reporting period;
- (d) Cash and cash equivalents, excluding restricted cash and cash equivalents and those that are to be exchanged or used to settle liabilities for at least twelve months after the reporting period.

B. Liabilities that meet one of the following criteria are classified as current liabilities; otherwise they are classified as non-current liabilities:

- (a) Liabilities that are expected to be settled in the normal operating cycle;
- (b) Liabilities that are held primarily for the purpose of trading;
- (c) Liabilities that are due to be settled within twelve months after the reporting period;
- (d) It does not have the right at the end of the reporting period to defer settlement of the liability at least twelve months after the reporting period.

**(5) Employee benefits**

**Pensions**

Pension cost for the interim period is calculated on a year-to-date basis by using the pension cost rate derived from the actuarial valuation at the end of the prior financial year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-off events. Also, the related information is disclosed accordingly.

**(6) Income tax**

The interim period income tax expense is recognised based on the estimated average annual effective income tax rate expected for the full financial year applied to the pretax income of the interim period, and the related information is disclosed accordingly.

**5. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY**

There was no significant change in the reporting period. Please refer to Note 5 in the consolidated financial statements for the year ended December 31, 2024.

**6. DETAILS OF SIGNIFICANT ACCOUNTS**

**(1) Cash and cash equivalents**

	December 31,		
	March 31, 2025	2024	March 31, 2024
Cash on hand and revolving funds	\$ 1,262	\$ 1,243	\$ 1,310
Checking accounts and demand deposits	1,450,049	1,761,009	2,557,835
Time deposits	577,578	582,368	420,000
	<u>\$ 2,028,889</u>	<u>\$ 2,344,620</u>	<u>\$ 2,979,145</u>

- A. The Group transacts with a variety of financial institutions all with high credit quality to disperse credit risk, and therefore, it expects that the probability of counterparty default is remote.
- B. The Group classified time deposits and pledged deposits with original maturities of more than three months that do not meet the definition of short-term cash commitments as 'financial assets at amortised cost - current' and 'financial assets at amortised cost – non current'. Please refer to Note 6(2) for details.
- C. The Group classified the pledged time deposits as 'financial assets at amortised cost'. Please refer to Notes 6(2) and 8 for details.

**(2) Financial assets at amortised cost**

Items	December 31,		
	March 31, 2025	2024	March 31, 2024
Current items:			
Time deposits with maturities of more than three months and not satisfy short-term cash commitments	\$ 112,500	\$ 112,500	\$ 12,500
Pledged time deposits	15,007	15,007	15,007
	<u>\$ 127,507</u>	<u>\$ 127,507</u>	<u>\$ 27,507</u>
Non-current items:			
Reserve accounts for syndicated loans	\$ 88,917	\$ 5,017	\$ 4,059

- A. Details of the Group's financial assets at amortised cost pledged to others as collateral are provided in Note 8.
- B. Information relating to credit risk of financial assets at amortised cost is provided in Note 12(2). The counterparties of the Group's investments in certificates of deposit are financial institutions with high credit quality, so the Group expects that the probability of counterparty default is remote.

(3) Notes and accounts receivable

	March 31, 2025	2024	March 31, 2024
Notes receivable	\$ 5,213	\$ -	\$ -
Less: Allowance for uncollectible accounts	<u>-</u>	<u>-</u>	<u>-</u>
	<u>\$ 5,213</u>	<u>\$ -</u>	<u>\$ -</u>
Accounts receivable	\$ 573,283	\$ 581,536	\$ 795,748
Less: Allowance for uncollectible accounts	(393,726)	(393,730)	(393,716)
	<u>\$ 179,557</u>	<u>\$ 187,806</u>	<u>\$ 402,032</u>

A. The ageing analysis of accounts receivable and notes receivable is as follows:

	March 31, 2025		December 31, 2024		March 31, 2024	
	Accounts	Notes	Accounts	Notes	Accounts	Notes
	receivable	receivable	receivable	receivable	receivable	receivable
Not past due	\$ 150,331	\$ 5,213	\$ 121,251	\$ -	\$ 283,001	\$ -
Within 30 days	-	-	62,925	-	-	-
31 to 90 days	25,514	-	-	-	1,134	-
91 to 180 days	3,730	-	3,652	-	117,905	-
Over 181 days	<u>393,708</u>	<u>-</u>	<u>393,708</u>	<u>-</u>	<u>393,708</u>	<u>-</u>
	<u>\$ 573,283</u>	<u>\$ 5,213</u>	<u>\$ 581,536</u>	<u>\$ -</u>	<u>\$ 795,748</u>	<u>\$ -</u>

The above ageing analysis is based on past due date.

B. As at March 31, 2025, December 31, 2024, March 31, 2024 and January 1, 2024, the balances of receivables from contracts with customers amounted to \$573,283 thousand, \$581,536 thousand, \$795,748 thousand and \$1,701,967 thousand, respectively.

C. The Group does not hold any collateral as security.

D. As at March 31, 2025, December 31, 2024 and March 31, 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the Group's notes receivable was \$5,213 thousand, \$0 thousand and \$0 thousand, respectively; As at March 31, 2025, December 31, 2024 and March 31, 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the Group's accounts receivable was \$179,557 thousand, \$187,806 thousand and \$402,032 thousand, respectively.

E. As at March 31, 2025, December 31, 2024 and March 31, 2024, loss allowance for accounts receivable all amounted to \$393,708 thousand, refer to Note 9(1) B for details.

F. The Group recognised \$238,338 thousand of refund liabilities for sales discounts and allowances that were expected to occur (shown as other current liabilities, others) as there was disagreement after the sales of goods between the Group's certain accounts receivable on March 31, 2024 and the customer's judgement based on the commercial conditions. For the aforementioned refund liabilities, after negotiation and mutual agreement with the sales customer, the Group processed the transaction at a discounted price in the third quarter of 2024.

G. Information relating to credit risk is provided in Note 12(2).

(4) Inventories

	March 31, 2025		
	Allowance		
	Cost	for valuation loss	Book value
Raw materials	\$ 116,361	(\$ 7,173)	\$ 109,188
Work in process	795,618	( 326,339)	469,279
Finished goods	140,837	( 36,316)	104,521
Merchandise	5,263	( 218)	5,045
	<u>\$ 1,058,079</u>	<u>(\$ 370,046)</u>	<u>\$ 688,033</u>

	December 31, 2024		
	Allowance		
	Cost	for valuation loss	Book value
Raw materials	\$ 112,451	(\$ 7,366)	\$ 105,085
Work in process	692,498	( 310,553)	381,945
Finished goods	162,659	( 26,813)	135,846
Merchandise	5,339	( 222)	5,117
	<u>\$ 972,947</u>	<u>(\$ 344,954)</u>	<u>\$ 627,993</u>

	March 31, 2024		
	Allowance		
	Cost	for valuation loss	Book value
Raw materials	\$ 149,229	(\$ 19,473)	\$ 129,756
Work in process	707,590	( 234,449)	473,141
Finished goods	145,274	( 59,929)	85,345
Merchandise	674	( 27)	647
	<u>\$ 1,002,767</u>	<u>(\$ 313,878)</u>	<u>\$ 688,889</u>

The cost of inventories recognised as expense for the period :

	Three-month period ended March 31,	
	2025	2024
Costs of goods sold	\$ 66,571	\$ 40,608
Loss on (gain from reversal of) decline in market value	25,092	( 9,269)
Revenue from sale of scraps	-	( 1)
Unallocated overhead	101,725	82,853
	<u>\$ 193,388</u>	<u>\$ 114,191</u>

For the three-month period ended March 31, 2024, the Group gradually sold certain inventories which previously provisioned loss on decline in market value, resulting in the reversal of inventory valuation losses.

**(5) Prepayments**

	March 31, 2025	December 31, 2024	March 31, 2024
Supplies inventory	\$ 130,475	\$ 136,601	\$ 151,432
Prepaid purchase	54,143	57,487	88,940
Residual tax credit	33,200	39,508	30,668
Others	5,734	6,450	8,699
	<u>\$ 223,552</u>	<u>\$ 240,046</u>	<u>\$ 279,739</u>

**(6) Financial assets at fair value through other comprehensive income**

Items	March 31, 2025	December 31, 2024	March 31, 2024
Non-current items:			
Listed stocks	\$ 61,129	\$ 61,129	\$ 61,129
Unlisted stocks	-	-	4,421
	61,129	61,129	65,550
Valuation adjustment	40,172	48,534	52,939
	<u>\$ 101,301</u>	<u>\$ 109,663</u>	<u>\$ 118,489</u>

- A. The Group has elected to classify equity instruments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments amounted to \$101,301 thousand, \$109,663 thousand and \$118,489 thousand as at March 31, 2025, December 31, 2024 and March 31, 2024, respectively.
- B. On April 16, 2024, the Group recognised the loss arising from derecognition of marketable securities whose fair value was \$135 thousand due to the dissolution of Hematech Biotherapeutics Inc, resulting to an accumulated loss on disposal of \$4,421 thousand.
- C. Amounts recognised in profit or loss and other comprehensive income in relation to the financial assets at fair value through other comprehensive income are listed below:

	Three-month period ended March 31,	
	2025	2024
<u>Equity instruments at fair value through other comprehensive income</u>		
Fair value change recognised in other comprehensive income	(\$ 8,362)	\$ 12,629

(7) Property, plant and equipment

	Three-month period ended March 31, 2025				
	Beginning balance	Additions	Decreases	Transfers	Ending balance
<u>Cost</u>					
Land	\$ 14,357	\$ -	\$ -	\$ -	\$ 14,357
Buildings and structures	2,143,366	1,932	( 440)	-	2,144,858
Machinery equipment	2,314,834	3,113	-	4,063	2,322,010
Transportation equipment	4,171	-	-	-	4,171
Other fixed assets	1,207,868	1,070	-	-	1,208,938
Construction in progress and equipment under acceptance	1,378,948	62,009	-	22,723	1,463,680
	<u>7,063,544</u>	<u>\$ 68,124</u>	<u>(\$ 440)</u>	<u>\$ 26,786</u>	<u>7,158,014</u>
<u>Accumulated depreciation</u>					
Buildings and structures	( 992,685)	(\$ 11,465)	\$ 440	\$ -	( 1,003,710)
Machinery equipment	( 1,404,707)	( 22,924)	-	-	( 1,427,631)
Transportation equipment	( 3,137)	( 65)	-	-	( 3,202)
Other fixed assets	( 920,827)	( 6,179)	-	-	( 927,006)
	<u>( 3,321,356)</u>	<u>(\$ 40,633)</u>	<u>\$ 440</u>	<u>\$ -</u>	<u>( 3,361,549)</u>
	<u>\$ 3,742,188</u>				<u>\$ 3,796,465</u>

	Three-month period ended March 31, 2024		
	Beginning balance	Additions	Ending balance
<u>Cost</u>			
Land	\$ 14,357	\$ -	\$ 14,357
Buildings and structures	2,137,561	3,761	2,141,322
Machinery equipment	2,327,411	965	2,328,376
Transportation equipment	4,171	-	4,171
Other fixed assets	1,203,175	1,178	1,204,353
Construction in progress and equipment under acceptance	1,028,795	31,271	1,060,066
	<u>6,715,470</u>	<u>\$ 37,175</u>	<u>6,752,645</u>
<u>Accumulated depreciation</u>			
Buildings and structures	( 942,022)	(\$ 15,609)	( 957,631)
Machinery equipment	( 1,330,255)	( 23,442)	( 1,353,697)
Transportation equipment	( 2,876)	( 65)	( 2,941)
Other fixed assets	( 895,991)	( 6,187)	( 902,178)
	<u>( 3,171,144)</u>	<u>(\$ 45,303)</u>	<u>( 3,216,447)</u>
	<u>\$ 3,544,326</u>		<u>\$ 3,536,198</u>

Note: The aforementioned property, plant and equipment were all for its own use.

A. Amount of borrowing costs capitalised as part of property, plant and equipment and the range of the interest rates for such capitalisation are as follows:

	Three-month period ended March 31,	
	2025	2024
Amount capitalised	\$ 10,105	\$ 8,079
Range of the interest rate for capitalisation	2.35%	2.22 ~ 2.30%

B. Information about the property, plant and equipment that were pledged to others as collaterals is provided in Note 8.

(8) Intangible assets

	Three-month period ended March 31, 2025		
	Beginning balance	Additions	Ending balance
<u>Cost</u>			
Authorization techniques	\$ 427,828	\$ -	\$ 427,828
Internal production cost	232,706	-	232,706
Computer software	47,153	250	47,403
	<u>707,687</u>	<u>\$ 250</u>	<u>707,937</u>
<u>Accumulated amortisation</u>			
Authorization techniques	( 270,893)	( 3,230)	( 274,123)
Internal production cost	( 219,304)	( 1,489)	( 220,793)
Computer software	( 41,756)	( 1,043)	( 42,799)
	<u>( 531,953)</u>	<u>( \$ 5,762)</u>	<u>( 537,715)</u>
<u>Accumulated impairment</u>			
Authorization techniques	( 127,874)	\$ -	( 127,874)
	<u>\$ 47,860</u>		<u>\$ 42,348</u>
Three-month period ended March 31, 2024			
	Beginning balance	Additions	Ending balance
<u>Cost</u>			
Authorization techniques	\$ 427,828	\$ -	\$ 427,828
Internal production cost	232,706	-	232,706
Computer software	46,123	680	46,803
	<u>706,657</u>	<u>\$ 680</u>	<u>707,337</u>
<u>Accumulated amortisation</u>			
Authorization techniques	( 257,978)	( 3,229)	( 261,207)
Internal production cost	( 213,347)	( 1,489)	( 214,836)
Computer software	( 36,993)	( 1,239)	( 38,232)
	<u>( 508,318)</u>	<u>( \$ 5,957)</u>	<u>( 514,275)</u>
<u>Accumulated impairment</u>			
Authorization techniques	( 127,874)	\$ -	( 127,874)
	<u>\$ 70,465</u>		<u>\$ 65,188</u>

Details of amortisation on intangible assets are as follows:

	Three-month period ended March 31,	
	2025	2024
Operating costs	\$ 4,718	\$ 4,718
General and administrative expenses	1,044	1,239
	<u>\$ 5,762</u>	<u>\$ 5,957</u>

A. In March 2007, the Company entered into a technique transfer agreement with Crucell Switzerland AG (formerly Berna Biotech AG) in relation to flu vaccines and products. In accordance with the agreement, Crucell Switzerland AG transfers the manufacturing technique of flu vaccines to the Company and charges royalties. In addition, the Company commits to exclusively provide products manufactured with the transferred technique to Crucell Switzerland AG. After the technique is transferred, the royalty charge is capitalised and is amortised over the estimated economic life using the straight-line method. The significant terms and conditions under the agreement are set forth below:

- (a) The Company manufactures the antigens needed for flu vaccine “Inflexal V” with the transferred technique which was acquired from Crucell Switzerland AG.
- (b) The Company should build a plant which has sufficient capacity and complies with the European standards, such as GMP or Europe Pharmacopoeia, and acquire qualifications issued by domestic and foreign competent authorities to produce.

B. Intangible assets generated internally within the Company including all development, production and building up assets so that the intangible assets will be available for use, such as labour costs and materials costs, are amortised on a straight-line basis over the estimated economic life after mass production.

C. The future economic benefits of technique transferred from Crucell Switzerland AG has decreased under the Group’s assessment, which resulted in the impairment loss of the intangible assets. The Group has adjusted the carrying amount based on the recoverable amount, and recognised impairment loss. The accumulated impairment loss of abovementioned technique is recognised in the amount of \$127,874 thousand as at March 31, 2025.

(9) Other non-current assets

	March 31, 2025	December 31, 2024	March 31, 2024
Prepayments for business facilities	\$ 253,096	\$ 269,768	\$ 377,505
Refundable deposits	31,065	30,914	36,807
Others	4,760	4,987	5,667
	<u>\$ 288,921</u>	<u>\$ 305,669</u>	<u>\$ 419,979</u>

(10) Short-term borrowings

Type of borrowings	March 31, 2025	Interest rate range	Collateral
Bank borrowings			
Unsecured borrowings	\$ 400,000	2.48% ~ 2.58%	None
Type of borrowings	December 31, 2023	Interest rate range	Collateral
Bank borrowings			
Unsecured borrowings	\$ 500,000	2.48% ~ 2.58%	None
Type of borrowings	March 31, 2024	Interest rate range	Collateral
Bank borrowings			
Unsecured borrowings	\$ 540,000	2.40% ~ 2.48%	None

Interest expense recognised in profit or loss amounted to \$2,839 thousand and \$3,175 thousand for the three-month periods ended March 31, 2025 and 2024, respectively.

(11) Other payables

	March 31, 2025	December 31, 2024	March 31, 2024
Salaries payable	\$ 89,903	\$ 104,409	\$ 102,686
Payables on equipment	9,095	59,848	27,121
Royalty payables	1,376	14,494	230
Others	67,849	76,242	73,130
	\$ 168,223	\$ 254,993	\$ 203,167

(Remainder of page intentionally left blank)

(12) Long-term borrowings

Type of borrowings	Borrowing period and repayment term	Collateral	March 31, 2025
Secured borrowings			
Land Bank of Taiwan (lead and management bank)	From October 8, 2020 to October 7, 2030; Term loan A is to be repaid with installments starting from October 2022; Term loan B is to be repaid with installments starting from October 2023. Term loan C is to be repaid with installments starting from July 2023 and is revolving.	Land, buildings and machinery equipment	\$ 2,218,300
Unsecured borrowings			
Chang Hwa Bank	From May 28, 2020 to May 28, 2025; Repaid with installments starting from June 2020.	Note 1	183
Taichung Commercial Bank	From June 1, 2020 to June 1, 2025; Repaid with installments starting from July 2020.	Note 1	264
Mega International Commercial Bank	From September 10, 2024 to September 9, 2029; Repaid with installments starting from October 2024.	Note 1 Note 2	22,494
Less: Current portion			2,241,241
Interest rate range			(523,171)
			\$ 1,718,070
			<u>2.31%~2.85%</u>

Type of borrowings	Borrowing period and repayment term	Collateral	December 31, 2024
<b>Secured borrowings</b>			
Land Bank of Taiwan (lead and management bank)	From October 8, 2020 to October 7, 2030; Term loan A is to be repaid with installments starting from October 2022; Term loan B is to be repaid with installments starting from October 2023. Term loan C is to be repaid with installments starting from July 2023 and is revolving.	Land, buildings and machinery equipment	\$ 2,018,300
<b>Unsecured borrowings</b>			
Chang Hwa Bank	From May 28, 2020 to May 28, 2025; Repaid with installments starting from June 2020.	Note 1	458
Taichung Commercial Bank	From June 1, 2020 to June 1, 2025; Repaid with installments starting from July 2020.	Note 1	526
Mega International Commercial Bank	From September 10, 2024 to September 9, 2029; Repaid with installments starting from October 2024.	Note 1 Note 2	6,045
			2,025,329
Less: Current portion			(320,044)
			\$ 1,705,285
Interest rate range			2.31%~2.85%

Type of borrowings	Borrowing period and repayment term	Collateral	March 31, 2024
<b>Secured borrowings</b>			
Land Bank of Taiwan (lead and management bank)	From October 8, 2020 to October 7, 2030; Term loan A is to be repaid with installments starting from October 2022; Term loan B is to be repaid with installments starting from October 2023. Term loan C is to be repaid with installments starting from July 2023 and is revolving	Land, buildings and machinery equipment	\$ 2,536,100
<b>Unsecured borrowings</b>			
Chang Hwa Bank	From May 28, 2020 to May 28, 2025; Repaid with installments starting from June 2020.	Note 1	1,283
Taichung Commercial Bank	From June 1, 2020 to June 1, 2025; Repaid with installments starting from July 2020.	Note 1	
			1,302
Less: Current portion			2,538,685
		(	669,938)
		\$	1,868,747
Interest rate range			2.18%~2.71%

Note 1: The guarantor is Small and Medium Enterprise Credit Guarantee Fund of Taiwan. Therefore, no collateral was pledged.

Note 2: The liability is jointly guaranteed by the representative of ENIMMUNE CORPORATION, a subsidiary of the Group.

- A. On July 14, 2020, the Company entered into a syndicated facility agreement with Land Bank of Taiwan as Management Bank and other banks, including First Commercial Bank, Mega International Commercial Bank, Taiwan Business Bank, Agribank, Bank of Panhsin, Taichung Commercial Bank and Chang Hwa Bank and Taiwan Cooperative Bank and obtained a credit line in the amount of \$4,200,000 thousand, consisting of Tranche A: non-revolving long-term credit line of \$1,300,000 thousand and Tranche B: non-revolving medium-term credit line of \$1,400,000 thousand and Tranche C: revolving medium-term credit line of \$1,500,000 thousand.
- B. Under the syndicated secured facility agreement as stated above:
  - (a) The Company shall obtain, maintain, update or comply with any grant, approval and certification required by the competent authorities.

- (b) The Company's net tangible assets shall not be less than \$370,000 thousand before the loan is settled.
- (c) The Company has responsibility of notifying Management Bank via confirmation letters if any significant investment equivalent to or over \$100,000 thousand is resolved by the Board of Directors.
- (d) The fund obtained in this agreement shall not be illegally diverted to and used in Mainland China.
- (e) Before the syndicated facility agreement has made payment, the Company may not do the following without written approval by all banks:
  - i. The Company is not allowed to merge with other companies or split up.
  - ii. The Company is not allowed to change the main operating businesses.
  - iii. The Company is not allowed to sell, lease, transfer, lend, pledge or dispose of whole or main parts of its business assets.
  - iv. Unless allowed under the Operational Procedures for Lending of Company Funds and the Operational Procedures for Endorsements and Guarantees, the Company should not provide loans or endorsements and guarantees to others.
  - v. The Company is not allowed to distribute any cash dividends upon occurrence or expected occurrence of default on the contract.
- (f) If the borrower fails to comply with any one of the above, the Company shall immediately repay interests and all outstanding balances of the loan. The Company did not violate above restrictions.

(13) Pensions

- A. (a) The Company and its domestic subsidiaries have a defined benefit pension plan in accordance with the Labor Standards Act, covering all regular employees' service years prior to the enforcement of the Labor Pension Act on July 1, 2005 and service years thereafter of employees who chose to continue to be subject to the pension mechanism under the Labor Standards Act. Under the defined benefit pension plan, two units are accrued for each year of service for the first 15 years and one unit for each additional year thereafter, subject to a maximum of 45 units. Pension benefits are based on the number of units accrued and the average monthly salaries and wages of the last 6 months prior to retirement. The Company and its domestic subsidiaries contribute monthly an amount equal to 2% of the employees' monthly salaries and wages to the retirement fund deposited with Bank of Taiwan, the trustee, under the name of the independent retirement fund committee. Also, the Company and its domestic subsidiaries would assess the balance in the aforementioned labor pension reserve account by December 31, every year. If the account balance is insufficient to pay the pension calculated by the aforementioned method to the employees expected to qualify for retirement in the following year, the Company and its domestic subsidiaries will make contributions for the deficit by next March.

(b) The pension costs under defined contribution pension plans of the Company for the three-month periods ended March 31, 2025 and 2024 were \$0 thousand and \$3 thousand, respectively.

(c) Expected contributions to the defined benefit pension plans of the Group for the year ending December 31, 2025 amount to \$297 thousand.

B. (a) Effective July 1, 2005, the Company and its domestic subsidiaries have established a defined contribution pension plan (the “New Plan”) under the Labor Pension Act (the “Act”), covering all regular employees with R.O.C. nationality. Under the New Plan, the Company and its domestic subsidiaries contribute monthly an amount based on 6% of the employees’ monthly salaries and wages to the employees’ individual pension accounts at the Bureau of Labor Insurance. The benefits accrued are paid monthly or in lump sum upon termination of employment.

(b) The pension costs under defined contribution pension plans of the Group for the three-month periods ended March 31, 2025 and 2024, were \$4,954 thousand and \$4,869 thousand, respectively.

(14) Share-based payment

A. For the three-month periods ended March 31, 2025 and 2024, the Group’s share-based payment arrangements were as follows:

Type of arrangement	Grant date	Quantity granted	Vested period	Vesting conditions	Footnote
Adimmune Corporation’s 2020~2023 years issuance of employees bonus shares	2020.12.18	920 units	3 years	Service vested	Note 1
Enimmune Corporation’s 2022~2032 years issuance of the employee stock options certificates	2022.8.17	2,400 units	10 years	Service vested	Notes 2, 3 and 4
Adimmune Corporation’s 2023~2026 issuance of employees bonus shares	2023.8.11	920 units	3 years	Service vested	Note 5
Enimmune Corporation’s cash capital increase reserved for employee preemption	2024.3.25	392.5 units	-	Vested	Note 6

Note 1: For the years 2020~2023 issuance of employees bonus shares, the fair value of stock price of the Company was \$56.60 (in dollars), and expected option life was not specified. For the years ended December 31, 2024 and 2023, the Company granted 305 units. As of March 31, 2025, it has been fully given and used.

Note 2: Subscribers can exercise stock options based on the following table after two years from the grant date. The duration of employee stock options is 10 years, and employee stock options cannot be transferred, pledged, donated, or disposed in any other method except for meeting the regulation specified in the terms.

Cumulatively exercisable ratio of employee stock options during the grant period is as follows:

Service periods of employees (year)	Vesting ratio
2 years	30%
3 years	60%
4 years	100%

Note 3: Upon receiving the restricted stocks, if employees violate the employment contract, working policy or have other significant defaults, the Company has the right to recover and retire the employee stock options which have no exercise right yet.

Note 4: The aforementioned periods and ratio of rights can be adjusted by the Board of Directors, depending on the condition of each issuance.

Note 5: For the years 2023~2026 issuance of employees bonus shares, the fair value of stock price of the Company was \$33.85 (in dollars), and expected option life was not specified. As of March 31, 2025, the Company has ungranted 920 units.

Note 6: On March 12, 2024, the Board of Directors of the Company's subsidiary, Enimmune Corporation, resolved to increase its capital by issuing common shares of 6,250 thousand shares and reserved 15% of new shares issued in the total amount of 937.5 thousand shares for employee preemption in accordance with Article 267 of the Company Act. The grant date for the cash capital reserved for employee preemption was set on March 25, 2024, and no restrictions were placed on the voting right and dividend right of the transferred shares. According to the terms of employee stock options at cash capital increase of the subsidiary, Enimmune, Enimmune's and the Company's employees can participate in the share subscription when they are still in service as of the effective date of share subscription, of which the actual subscribed shares amounted to 392.5 thousand shares.

B. Details of the share-based payment arrangements are as follows:

Enimmune Corporation's years 2022~2032 issuance of the employee stock option certificates

	2025	
	No. of options	Weighted-average exercise price (in dollars)
Options outstanding at January 1	1,951	\$ 24.80
Options executed	-	-
Options forfeited	( 100)	-
Options outstanding at March 31	<u>1,851</u>	1,851
Options exercisable at March 31	<u>171</u>	171

  

	2024	
	No. of options	Weighted-average exercise price (in dollars)
Options outstanding at January 1	2,095	\$ 24.80
Options executed	-	-
Options forfeited	-	-
Options outstanding at March 31	<u>2,095</u>	2,095
Options exercisable at March 31	<u>-</u>	-

C. The fair value of stock options granted on grant date is measured using the Black-Scholes option-pricing model. Relevant information is as follows:

Type of arrangement	Grant date	Expected						
		Stock price (in dollars)	Exercise price (in dollars)	Expected volatility (%)	Expected option life (year)	Expected dividend rate (%)	Risk-free interest rate (%)	Fair value per unit
Issuance of the employee stock option certificates	2022.8.17	29.02	24.80	48.85~ 49.81%	6~7	-	1.1264~ 1.1450%	14.7931~ 15.9028
Cash capital increase reserved for employee preemption	2024.3.25	32.63	32	27.55%	0.1479	-	1.1674%	1.7339

Note 1: The market price adopted the fair value of the Company's common shares at the grant date, taking into consideration liquidity premium.

Note 2: Expected price volatility rate was estimated by using the stock prices of the most recent period with length of this period approximate to the length of the stock options' expected life, and the standard deviation of return on the stock during this period.

D. On June 9, 2022, the Board of Directors of the subsidiary, Enimmune Corporation, resolved to implement a long-service incentive plan and make a plan for transferring shares to employees through repurchasing shares in accordance with the Securities and Exchange Act Article 28 and the “Regulations Governing Share Repurchase by Exchange-Listed and OTC-Listed Companies”. According to the plan of transferring shares to employees through repurchasing shares of 2022 of the subsidiary, Enimmune Corporation, employees of the Group and the parent company, Adimmune Corporation, who are on board before the effective date of share subscription or employees of the Company and foreign and domestic controlled companies or subsidiaries (including part-time employees and consultants) who have specific contribution to the Company and have been reported to and been approved by the Chairman are entitled to subscribe to shares based on the subscription amount specified in Article 5 of the plan.

E. Expenses incurred on share-based payment transactions are shown below :

	Three-month period ended March 31,	
	2025	2024
Compensation cost	\$ 2,865	\$ 7,681

**(15) Provisions**

	Stock Buyback or Repurchase		
	March 31, 2025	December 31, 2024	March 31, 2024
At January 1, 2025 (March 31)	\$ 17,248		

  

	March 31, 2025	December 31, 2024	March 31, 2024
Current	\$ 17,248	\$ 17,248	\$ -

**Equity Repurchase :**

As described in Note 4(3), the subsidiary, Enimmune Corporation, intends to negotiate with RMT Company regarding the repurchase of equity. The preliminary plan is for Anterro Biotech to buy back the entire 45% stake in EB Company held by RMT Company for a total consideration of USD 4.5 million. Enimmune Corporation has assessed the most likely outcome of the agreement, considering the original shareholder agreement with RMT Company at the time of the initial investment. Enimmune Corporation plans to compensate RMT Company with interest in consideration of the market borrowing rate. Consequently, Enimmune Corporation Biotech has estimated a provision for liabilities amounting to NT\$17,248 thousand, which is expected to be settled upon the execution of the equity repurchase agreement. The loss recognized from this provision for liabilities is recorded under other gains and losses for the year ended December 31, 2024.

**(16) Share capital**

A. As of March 31, 2025, the Company's authorised capital was \$7,000,000 thousand, consisting of 700,000 thousand shares of ordinary stock (including 15,000 thousand shares reserved for employee stock options), and the paid-in capital was \$4,295,078 thousand with a par value of \$10 (in dollars) per share. All proceeds from shares issued have been collected.

Movements in the number of the Company's ordinary shares outstanding are as follows:

	2025	2024
	(thousand shares)	(thousand shares)
At January 1 (March 31)	421,508	421,508

B. Treasury shares

(a) Reason for share reacquisition and movements in the number of the Company's treasury shares are as follows:

At March 31, 2025			
Name of company holding the shares	Reason for reacquisition	Number of shares (in thousands)	Carrying amount
Adimmune Corporation	To be reissued to employees	8,000	\$ 292,538

At December 31, 2024			
Name of company holding the shares	Reason for reacquisition	Number of shares (in thousands)	Carrying amount
Adimmune Corporation	To be reissued to employees	8,000	\$ 292,538

At March 31, 2024			
Name of company holding the shares	Reason for reacquisition	Number of shares (in thousands)	Carrying amount
Adimmune Corporation	To be reissued to employees	8,000	\$ 292,538

(b) To motivate employees and enhance their team cohesiveness, on June 9, 2022 and November 11, 2022, the Board of Directors resolved repurchasing of treasury shares in the expected amount of 8,000 thousand shares in order to transfer them to employees. As of March 31, 2025, the balance of the treasury shares repurchased was \$292,538 thousand.

(c) Pursuant to the R.O.C. Securities and Exchange Act, the number of shares bought back as treasury share should not exceed 10% of the number of the Company's issued and outstanding shares and the amount bought back should not exceed the sum of retained earnings, paid-in capital in excess of par value and realised capital surplus.

(d) Pursuant to the R.O.C. Securities and Exchange Act, treasury shares should not be pledged as collateral and is not entitled to dividends before it is reissued.

(e) Pursuant to the R.O.C. Securities and Exchange Act, treasury shares should be reissued to the employees within five years from the reacquisition date and shares not reissued within the five-year period are to be retired. Treasury shares to enhance the Company's credit rating and the stockholders' equity should be retired within six months of acquisition.

(17) Capital surplus

Pursuant to the R.O.C. Company Act, capital surplus arising from paid-in capital in excess of per value on issuance of common stocks and donations can be used to cover accumulated deficit or to issue new stocks or cash to shareholders in proportion to their share ownership, provided that the Company has no accumulated deficit. Further, the R.O.C. Securities and Exchange Law requires that the amount of capital surplus to be capitalised mentioned above should not exceed 10% of the paid-in capital each year. Capital surplus should not be used to cover accumulated deficit unless the legal reserve is insufficient.

(18) Retained earnings

- A. Under the Company's Articles of Incorporation, the current year's earnings, if any, shall first be used to pay all taxes and recover prior year's losses and then 10% of the remaining amount shall be appropriate as legal reserve. The remainder, if any, to be retained or to be appropriated shall be resolved by the stockholders at the stockholders' meeting.
- B. The Company operates in the biotechnology industry, which has the industry life cycle. Dividends shall be allocated after taking into consideration several factors including current and future investment environment, capital requirements, domestic and foreign competition, capital budget, shareholders' interests, balanced dividends, and the Company's long-term financial plan. Dividend distribution plans are to be proposed by the Board of Directors and presented for a final resolution in the shareholders' meeting on a yearly basis.
- C. Except for covering accumulated deficit or issuing new stocks or cash to shareholders in proportion to their share ownership, the legal reserve shall not be used for any other purpose. The use of legal reserve for the issuance of stocks or cash to shareholders in proportion to their share ownership is permitted, provided that the distribution of the reserve is limited to the portion in excess of 25% of the Company's paid-in capital.
- D. On March 12, 2025, the Board of Directors of the Company proposed not to distribute dividends in accordance with laws after taking into account the distributable profit for the year ended December 31, 2024. The aforementioned proposal of 2024 earnings distribution are pending approval by the shareholders' meeting.
- E. On March 12, 2024, the Board of Directors of the Company proposed the earnings appropriation. However, the Company did not distribute earnings as the Company had loss for the year ended December 31, 2023. The aforementioned earnings appropriation of year 2023 had been approved by the shareholders during their meeting on June 21, 2024.
- F. Information relating to employees' compensation and directors' remuneration is provided in Note 6(23).

(19) Operating revenue

Information on products and services

A. The Group engages in the manufacture and trade of vaccines, modern medicine products and testing reagents. Details of revenue are as follows:

	Three-month period ended March 31, 2025		
	Adimmune Corporation	Enimmune Corporation	Total
Revenue from professional packing service	\$ 59,162	\$ -	\$ 59,162
Sales revenue	221	11,787	12,008
Other revenue	934	-	934
	<u>\$ 60,317</u>	<u>\$ 11,787</u>	<u>\$ 72,104</u>

  

	Three-month period ended March 31, 2024		
	Adimmune Corporation	Enimmune Corporation	Total
Revenue from professional packing service	\$ 29,236	\$ -	\$ 29,236
Sales revenue	1,857	3,723	5,580
Other revenue	9,062	-	9,062
	<u>\$ 40,155</u>	<u>\$ 3,723</u>	<u>\$ 43,878</u>

  

	Three-month period ended March 31, 2025		
	Adimmune Corporation	Enimmune Corporation	Total
Timing of revenue recognition			
Over time	\$ 59,162	\$ -	\$ 59,162
At a point in time	1,155	11,787	12,942
	<u>\$ 60,317</u>	<u>\$ 11,787</u>	<u>\$ 72,104</u>

  

	Three-month period ended March 31, 2024		
	Adimmune Corporation	Enimmune Corporation	Total
Timing of revenue recognition			
Over time	\$ 29,236	\$ -	\$ 29,236
At a point in time	10,919	3,723	14,642
	<u>\$ 40,155</u>	<u>\$ 3,723</u>	<u>\$ 43,878</u>

## B. Contract assets and liabilities

(a) The Group has recognised the following revenue-related contract assets and liabilities:

	March 31, 2025	December 31, 2024	March 31, 2024	January 1, 2024
Contract assets:				
Service	\$ 334,933	\$ 334,933	\$ 334,933	\$ 334,933
Contract liabilities:				
Advance sales receipts	\$ 68,665	\$ 9,394	\$ 93,805	\$ 21,812

(b) Revenue recognised that was included in the contract liability balance at the beginning of the three-month periods ended March 31, 2025 and 2024 was \$7 thousand and \$3,058 thousand, respectively.

(c) Long-term contracts that are fully unsatisfied

As of March 31, 2025, the aggregate amount of the transaction price and milestone payments allocated to long-term development and manufacturing service agreements with customers that are not yet fully satisfied amounted to NT\$1,654,154 thousand. Management expects to recognize the related revenue in future periods. For the three-month periods ended March 31, 2025 and 2024, the Group recognized service revenue of NT\$0 thousand, based on the progress of contract fulfillment.

### (20) Interest income

	Three-month period ended March 31,	
	2025	2024
Interest income from bank deposits	\$ 3,232	\$ 1,461
Other interest income	9	9
	\$ 3,241	\$ 1,470

### (21) Other income

	Three-month period ended March 31,	
	2025	2024
Grant revenue	\$ -	\$ 901
Other non-operating income	789	1,033
	\$ 789	\$ 1,934

For the three-month period ended March 31, 2024, all of the Group's grant revenue was derived from government subsidies. Please refer to Note 9(2) for details of certain grant agreements.

(22) Other gains and losses

	Three-month period ended March 31,	
	2025	2024
Gains arising from lease modifications	\$ -	\$ 1
Net currency exchange gains	10,986	10,339
Other gains and losses (Note)	-	(8,980)
	<u>\$ 10,986</u>	<u>\$ 1,360</u>

(23) Employee benefit expense, depreciation and amortisation

Nature	Three-month period ended March 31, 2025		
	Operating cost	Operating expense	Total
Employee benefit expense			
Wages and salaries	\$ 78,011	\$ 53,759	\$ 131,770
Employee stock options	297	2,568	2,865
Labor and health insurance fees	7,320	3,779	11,099
Pension costs	3,070	1,884	4,954
Directors' remuneration	-	2,178	2,178
Other personnel expenses	1,136	2,557	3,693
	<u>\$ 89,834</u>	<u>\$ 66,725</u>	<u>\$ 156,559</u>
Depreciation	<u>\$ 37,533</u>	<u>\$ 9,295</u>	<u>\$ 46,828</u>
Amortisation	<u>\$ 4,718</u>	<u>\$ 1,270</u>	<u>\$ 5,988</u>

Nature	Three-month period ended March 31, 2024		
	Operating cost	Operating expense	Total
Employee benefit expense			
Wages and salaries	\$ 69,454	\$ 40,058	\$ 109,512
Employee stock options	585	7,096	7,681
Labor and health insurance fees	7,054	3,326	10,380
Pension costs	3,099	1,773	4,872
Directors' remuneration	-	1,555	1,555
Other personnel expenses	1,298	2,438	3,736
	<u>\$ 81,490</u>	<u>\$ 56,246</u>	<u>\$ 137,736</u>
Depreciation	<u>\$ 42,092</u>	<u>\$ 7,817</u>	<u>\$ 49,909</u>
Amortisation	<u>\$ 4,718</u>	<u>\$ 1,466</u>	<u>\$ 6,184</u>

A. In accordance with the Articles of Incorporation of the Company, a ratio of distributable profit of the current year, after covering accumulated losses, shall be distributed as employees' compensation and directors' remuneration. The ratio shall be 1%~10% for employees' compensation and shall not be higher than 5% for directors' remuneration.

B. For the three-month periods ended March 31, 2025 and 2024, there were no employees' compensation and directors' remuneration accrued as the Company generated loss before tax. For the three-month periods ended March 31, 2025 and 2024, employees' compensation and directors' remuneration will not be distributed as the Company generated loss before tax. Information regarding employees' compensation and directors' remuneration as resolved by the Board of Directors will be posted in the "Market Observation Post System" at the website of the Taiwan Stock Exchange.

(24) Finance costs

	Three-month period ended March 31,	
	2025	2024
Interest expense:		
Bank borrowings	\$ 15,220	\$ 17,827
Interest expense on lease liabilities	402	351
Less: Capitalisation of qualifying assets	(10,105)	(8,079)
	<u>\$ 5,517</u>	<u>\$ 10,099</u>

(25) Income tax

A. Reconciliation between income tax benefit and accounting profit:

	Three-month period ended March 31,	
	2025	2024
Tax calculated based on loss before tax and statutory tax rate	(\$ 58,044)	(\$ 44,154)
Expenses disallowed by tax regulation	7,166	4,259
Temporary difference not recognised as deferred tax assets	1,434	(4,601)
Loss carryforward not recognised as deferred tax assets	<u>49,444</u>	<u>44,496</u>
Income tax expense	<u>\$ -</u>	<u>\$ -</u>

B. The income tax returns of the Group through 2022 have been assessed and approved by the Tax Authority.

C. The income tax returns of the Group's subsidiary, Enimmune Corporation, through 2023 have been assessed and approved by the Tax Authority.

D. The income tax returns of the Group's subsidiary, Eggs Corporation, through 2023 have been assessed and approved by the Tax Authority.

E. The income tax returns of the Group's indirect subsidiary, Animmune Corporation, through 2023 have been assessed and approved by the Tax Authority.

(26) Losses per share

Three-month period ended March 31, 2025			
	Weighted average number of ordinary shares outstanding	Losses per share	
Amount after tax	(share in thousands)	(in dollars)	
<u>Basic (diluted) losses per share</u>			
Loss attributable to ordinary shareholders of the parent	(\$ 223,253)	421,508	(\$ 0.53)
Three-month period ended March 31, 2024			
	Weighted average number of ordinary shares outstanding	Losses per share	
	Amount after tax	(share in thousands)	(in dollars)
<u>Basic (diluted) losses per share</u>			
Loss attributable to ordinary shareholders of the parent	(\$ 183,970)	421,508	(\$ 0.44)

(27) Transactions with non-controlling interest

A. Capital increase by subsidiary without full subscription by the Group:

The Group's subsidiary, Enimmune Corporation, increased its capital by issuing new shares on May 27, 2024. The Group's shareholding ratio decreased by 0.68% due to not acquiring shares proportionately to its ownership. The transaction increased non-controlling interest and equity attributable to owners of the parent by \$102,042 thousand and \$11,637 thousand, respectively.

B. Exercise of employee stock options by subsidiary:

On August 17, 2022, the board of directors of ENIMMUNE CORPORATION resolved to issue employee stock options (refer to Note 6(14) for details). Upon exercise of the stock options, November 11, 2024 was set as the record date for the issuance of new shares. As a result of the issuance, the Group's shareholding in the subsidiary decreased by 0.06%. This transaction resulted in an increase in non-controlling interests of NT\$2,064 thousand.

(28) Supplemental cash flow information

Investing activities with partial cash payments

	Three-month period ended March 31,	
	2025	2024
Purchase of property, plant and equipment	\$ 68,124	\$ 37,175
Add: Opening balance of payable on equipment	59,848	18,238
Less: Ending balance of payable on equipment	( 9,095)	( 27,121)
Less: Amount capitalised	( 10,105)	( 8,079)
Cash paid during the period	<u>\$ 108,772</u>	<u>\$ 20,213</u>
	Three-month period ended March 31,	
	2025	2024
Less: Opening balance of prepayments for business facilities	(\$ 269,768)	(\$ 363,802)
Add: Ending balance of prepayments for business facilities	253,096	377,505
Add: Unfinished construction and equipment under acceptance	26,786	-
Cash paid during the period	<u>\$ 10,114</u>	<u>\$ 13,703</u>

(29) Changes in liabilities from financing activities

	Short-term borrowings	Long-term borrowings (Note)	Lease liabilities (Note)	Liabilities from financing activities - gross
At January 1, 2025	\$ 500,000	\$ 2,025,329	\$ 71,346	\$ 2,596,675
Changes in cash flow from financing activities	( 100,000)	215,912	( 7,972)	107,940
Changes in other non-cash items	-	-	9,185	9,185
At March 31, 2025	<u>\$ 400,000</u>	<u>\$ 2,241,241</u>	<u>\$ 72,559</u>	<u>\$ 2,713,800</u>

Note: Including current portion.

	Short-term borrowings	Long-term borrowings (Note)	Lease liabilities (Note)	Liabilities from financing activities - gross
At January 1, 2024	\$ 54,000	\$ 2,539,215	\$ 63,415	\$ 2,656,630
Changes in cash flow from financing activities	-	( 530)	( 4,717)	( 5,247)
Changes in other non-cash items	-	-	4,672	4,672
At March 31, 2024	<u>\$ 54,000</u>	<u>\$ 2,538,685</u>	<u>\$ 63,370</u>	<u>\$ 2,656,055</u>

Note: Including current portion.

## 7. RELATED PARTY TRANSACTIONS

### Key management compensation

	Three-month period ended March 31,	
	2025	2024
Short-term employee benefits	\$ 27,170	\$ 17,658
Post-employment benefits	796	677
Share-based payments	2,841	6,890
	<u>\$ 30,807</u>	<u>\$ 25,225</u>

## 8. PLEDGED ASSETS

The Group's assets pledged as collateral are as follows:

Pledged asset	Book value			Purpose
	March 31, 2025	December 31, 2024	March 31, 2024	
Property, plant and equipment	\$ 1,183,759	\$ 1,164,912	\$ 1,216,569	Long-term borrowings
Special reserve account and pledged account (included in financial assets at amortised cost - non-current)	88,917	5,017	87,959	Long-term borrowings
Time deposits (included in financial assets at amortised cost - current)	15,007	15,007	15,007	Performance margin for bidding
Refundable deposits (included in other current assets and other non-current assets)	<u>82,721</u>	<u>82,581</u>	<u>105,019</u>	Performance margin for bidding
	<u>\$ 1,370,404</u>	<u>\$ 1,267,517</u>	<u>\$ 1,424,554</u>	

## 9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT COMMITMENTS

### (1) Contingencies

A. On September 8, 2022, the Group's subsidiary, Enimmune Corporation ("Enimmune"), entered into a tri-party agreement with Everhealth Biomedical Materials Co., Ltd. ("Everhealth") and Sam Chun Dang Pharm. Co., Ltd. ("SCD company"). Pursuant to the agreement, Everhealth was obligated to pay Enimmune US\$1,437 thousand for goods and NT\$10,782 thousand for management service fees. As Everhealth failed to fulfill its payment obligations, Enimmune filed a civil lawsuit against Everhealth on November 7, 2022, seeking recovery of the aforementioned amounts US\$1,437 thousand for goods (equivalent to approximately NT\$47,669 thousand) and NT\$10,782 thousand for management service fees, respectively, totaling NT\$58,451 thousand. Furthermore, under the terms of the tri-party agreement, Enimmune's obligation to make payment to SCD company does not arise until payment from Everhealth is received. On October 31, 2023, the Civil Division of the Taiwan New Taipei District Court issued a first-instance ruling, ordering Everhealth to pay Enimmune the full amount of US\$1,437 thousand for goods (equivalent to

approximately NT\$47,669) and NT\$10,782 thousand for management service fees, respectively, totaling NT\$58,451 thousand, along with interest at an annual rate of 5% starting from September 18, 2022. As of December 31, 2024, the accrued interest amounted to approximately NT\$7,406 thousand. Everhealth filed an appeal for a second-instance trial on November 28. Additionally, on April 22, 2025, the Taiwan High Court rejected the appeal filed by Everhealth and ruled in favour of Enimmune in the second-instance trial. Everhealth shall pay the aforementioned amount to Enimmune. As of May 13, 2025, Everhealth has not filed an appeal for a third-instance trial.

B. The Group entered into a vaccine distribution contract with Beijing Shouhui Pharmaceutical Co. Ltd. (“Shouhui Company”) in December 2019 and had conducted transactions in subsequent years. For the year ended December 31, 2022, the Group shipped the goods after accepting the order from Shouhui Company. However, Shouhui Company did not make the payment according to the payment term agreed in the contract. The Group's receivables due from Shouhui Company was \$393,708 thousand. After failing to collect the payment from Shouhui Company, the Group officially issued a “notice of termination of contract” to Shouhui Company to terminate the contract on February 17, 2023, appointed a Beijing lawyer to file a litigation with the Fourth Intermediate People's Court of Beijing Municipality against Shouhui Company requesting it to make the payment and compensatory damage, applied for injunctive procedure and froze the main bank account of Shouhui Company. The Fourth Intermediate People's Court of Beijing Municipality had opened a court session on January 17, 2024 and rendered a decision that Shouhui Company shall pay the payment and compensatory damage to the Group on March 18, 2024. Shouhui Company thereupon had filed a pleading to appeal for a second trial on March 29, 2024. In July 2024, the High People's Court of Beijing Municipality rendered the same verdict. As it is unlikely that the recoverable amount of the receivables can be fully recovered based on the assessment, the Group had made full provision for expected credit loss.

C. In 2023, the Company entered into an embryo egg procurement agreement with Pofu Clean Livestock Farm (“Pofu”). A dispute subsequently arose from the agreement, wherein Pofu alleged that the Company failed to fulfill the guaranteed annual purchase volume of embryo eggs as stipulated in the contract. Accordingly, Pofu filed a civil lawsuit with the Taichung District Court in Taiwan, demanding compensation and outstanding payment for embryo eggs in the total amount of NT\$38,068 thousand. The Company has appointed legal counsel to respond to the lawsuit, which is currently under trial by the Taichung District Court. Based on the Company's assessment and consultation with its legal advisors, management believes that the likelihood of a favorable outcome is higher; however, the final result remains uncertain. The Company will continue to closely monitor the progress of the litigation. As of May 13, 2025, the case remains under legal proceedings.

(2) Commitments

A. Capital expenditure contracted for at the balance sheet date but not yet incurred is as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Property, plant and equipment	\$ 148,167	\$ 199,520	\$ 342,162

B. The Company has signed technical contracts relating to continuing development of vaccine of Enterovirus 71 (“EV 71”) with the Center for Disease Control, R.O.C. (“CDC”) and the National Health Research Institute (“NHRI”) in 2011. Details of each stage in the contracts are as follows:

(a) The Company has signed technical contracts relating to licensing technology of EV71 with CDC and NHRI in September 2011. The main commitments of the technology license are as follows:

- i. Licensing period: Starting from the date when the three parties sign the contracts.
- ii. Authorisation expense: The contracts are signed to pay in accordance with progress.

(b) The Company has signed “EV 71 vaccine Phase I clinical trial result authorisation” cooperation contract with CDC and NHRI in April 2013. NHRI has authorised the technology through non-exclusive license. Details of key commitments are as follows:

- i. Contract period: Starting from the date when the three parties sign the contract until 25 years after the Company’s first EV71 vaccine is authorised.
- ii. Authorisation fee: The Company pays authorization fee in accordance with contracted progress within 2 years after the contract is signed.

(c) In May 2020 and October 2022, the Company renewed the “Commission Service Contract” signed in May 2018 with NHRI to provide the Company with a development platform for vaccine. The main terms of the contract are as follows:

- i. Commission period: 2 years (2023.1.1~2024.12.31)
- ii. Commission expense: Service expense is paid each month.

(d) In January 2020, the Company has signed the “Commission Service Contract” with NHRI to provide the Company with cell culture platform for vaccine. The main terms of the contract are as follows:

Commission service fee: The contracts are signed to pay in accordance with progress.

C. The Company has signed a processing agreement with Shenzhen Techdow Pharmaceutical Co., LTD (“TECHDOW”).

The two companies’ cooperative injection technique, which is the Company’s packing techniques (aseptic prefilled injection packing techniques) along with TECHDOW’s pharmaceutical material (Enoxaparin sodium), has received EMA’s authorisation and is processed for mass production. Key commitments of the agreement are as follows:

(a) Contract period: 5 years after the completion of construction of the second aseptic injection packing line and production starting for TECHDOW’s products from the date of the first order by TECHDOW. Unless one party notifies the other a non-renewal no less than 6 months before the agreement expires, the agreement is automatically renewed every two years.

- (b) Processing price: By the process quantity in accordance with the agreement.
- (c) Other commitments: During the agreement period, the Company may not directly or indirectly produce same products for supply in any market.

D. For the year ended December 31, 2022, the Group's subsidiary, Enimmune Corporation ("Enimmune"), entered into an agreement with the Taipei Computer Association for Information Industry to implement the Phase 3 Clinical Testing Program of EV71 Vaccines Manufactured from Bioreactors on Healthy Children. The project period is from March 1, 2022 to February 2, 2025, and was extended on November 17, 2023, to November 30, 2025. The total approved subsidy amount is NT\$15,007 thousand. For the year ended December 31, 2023, subsidy income recognized amounted to NT\$2,471 thousand, and the related subsidy was received in December 2023.

The main rights and obligations of the agreement are listed as follows:

- (a) All results from Enimmune's implementation of the research program, including knowledge, technologies, and intellectual property belong to Enimmune. Enimmune has the responsibility to manage and apply these results.
- (b) If the source of the Taipei Computer Association's grant is the Executive Yuan's National Science and Technology Development Fund, Enimmune's ownership, management, and application of the research results shall be governed by the terms of Executive Yuan's National Science and Technology Development Fund Grant Contract.

#### **10. SIGNIFICANT DISASTER LOSS**

None.

#### **11. SIGNIFICANT SUBSEQUENT EVENTS**

None.

#### **12. OTHERS**

##### **(1) Capital management**

The Group's capital management is based on the industry where the Group is in, industry's future growth and product development to set an appropriate market share, set a corresponding capital expenditure. The management also considers operating funds calculated based on financial operation plans and consideration of operating profit and cash flow generated by product competitiveness to determine an appropriate capital structure.

(2) Financial instruments

A. Financial instruments by category

	December 31,		
	March 31, 2025	2024	March 31, 2024
<u>Financial assets</u>			
Financial assets at fair value through other comprehensive income			
- non-current	\$ 101,301	\$ 109,663	\$ 118,489
Financial assets at amortised cost			
Cash and cash equivalents	2,028,889	2,344,620	2,979,145
Financial assets at amortised cost			
- current	127,507	127,507	27,507
Notes receivable	5,213	-	-
Accounts receivable	179,557	187,806	402,032
Financial assets at amortised cost			
- non-current	88,917	5,017	87,959
Other receivables			
(shown as other current assets)	281	253	249
Refundable deposits			
(shown as other current assets and other non-current assets)	82,701	82,581	105,019
	<u>\$ 2,614,366</u>	<u>\$ 2,857,447</u>	<u>\$ 3,720,400</u>

	December 31,		
	March 31, 2025	2024	March 31, 2024
<u>Financial liabilities</u>			
Financial liabilities at amortised cost			
Short-term borrowings	\$ 400,000	\$ 500,000	\$ 540,000
Notes payable	7,381	60	2,788
Accounts payable	42,659	31,190	68,308
Other payables	168,223	254,993	203,167
Long-term borrowings			
(including current portion)	2,241,241	2,025,329	2,538,685
	<u>\$ 2,859,504</u>	<u>\$ 2,811,572</u>	<u>\$ 3,352,948</u>
Lease liabilities			
(including current portion)	\$ 72,559	\$ 71,346	\$ 63,370

B. Financial risk management policies

(a) The Group's activities expose it to a variety of financial risks: market risk (including foreign exchange risk, and interest rate risk), credit risk and liquidity risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial position and financial performance.

(b) Group treasury identifies, evaluates and hedges financial risks by closely cooperating with the Group's operating units. The Board of Directors provides written principles for overall risk management, as well as written policies covering specific areas and matters, such as foreign exchange risk, interest rate risk, and credit risk, use of derivative financial instruments and non-derivative financial instruments, and investment of excess liquidity.

C. Significant financial risks and degrees of financial risks

(a) Market risk

Foreign exchange risk

- i. The Group manages their foreign exchange risk against their functional currency. The Group is required to hedge their entire foreign exchange risk exposure via the Group treasury.
- ii. Foreign exchange risk between USD, JPY and EUR with NTD is mainly from exchange loss or profit arising from conversion of cash and cash equivalents and accounts receivable denominated in USD, JPY and EUR.
- iii. The Group's businesses involve some non-functional currency operations (the Company's functional currency: NTD; certain second-tier subsidiaries' functional currency: USD). The information on assets and liabilities denominated in foreign currencies whose values would be materially affected by the exchange rate fluctuations and analysis of foreign currency market risk arising from significant foreign exchange variation are as follows:

March 31, 2025

<b>(Foreign currency: functional currency)</b>	Foreign currency		Book value (NTD)	
	amount (In thousands)	Exchange rate		
<b>Financial assets</b>				
<b>Monetary items</b>				
USD : NTD	\$ 16,661	33.16	\$ 552,479	
JPY : NTD	396,500	0.22	87,230	
EUR : NTD	151	35.77	5,401	
RMB : NTD	22,683	4.55	103,208	
<b>Financial liabilities</b>				
<b>Monetary items</b>				
USD : NTD	\$ 105	33.26	\$ 3,492	

December 31, 2024

<b>(Foreign currency: functional currency)</b>	Foreign currency		Book value (NTD)	
	amount	Exchange rate		
	(In thousands)			
<b>Financial assets</b>				
<b>Monetary items</b>				
USD : NTD	\$ 10,318	32.74	\$ 337,811	
JPY : NTD	396,169	0.21	83,195	
EUR : NTD	137	33.94	4,650	
RMB : NTD	19,992	4.45	88,964	
<b>Financial liabilities</b>				
<b>Monetary items</b>				
USD : NTD	\$ 698	32.84	\$ 22,922	

March 31, 2024

<b>(Foreign currency: functional currency)</b>	Foreign currency		Book value (NTD)	
	amount	Exchange rate		
	(In thousands)			
<b>Financial assets</b>				
<b>Monetary items</b>				
USD : NTD	\$ 18,046	31.95	\$ 576,570	
JPY : NTD	396,133	0.21	83,188	
EUR : NTD	280	34.26	9,593	
RMB : NTD	108,879	4.38	476,890	
<b>Financial liabilities</b>				
<b>Monetary items</b>				
USD : NTD	\$ 346	32.05	\$ 11,089	

Three-month period ended March 31, 2025					
Sensitivity analysis					
	Degree of variation		Effect on profit or loss	Effect on other comprehensive income	
<b>(Foreign currency: functional currency)</b>					
<b>Financial assets</b>					
<b>Monetary items</b>					
USD : NTD	1%	\$	5,525	\$	-
JPY : NTD	1%		872		-
EUR : NTD	1%		54		-
RMB : NTD	1%		1,032		-
<b>Financial liabilities</b>					
<b>Monetary items</b>					
USD : NTD	1%	\$	35	\$	-
Three-month period ended March 31, 2024					
Sensitivity analysis					
	Degree of variation		Effect on profit or loss	Effect on other comprehensive income	
<b>(Foreign currency: functional currency)</b>					
<b>Financial assets</b>					
<b>Monetary items</b>					
USD : NTD	1%	\$	5,766	\$	-
JPY : NTD	1%		832		-
EUR : NTD	1%		96		-
RMB : NTD	1%		4,769		-
<b>Financial liabilities</b>					
<b>Monetary items</b>					
USD : NTD	1%	\$	111	\$	-

Total exchange gain (loss), including realised and unrealised, arising from significant foreign exchange variation on the monetary items held by the Group for the three-month periods ended March 31, 2025 and 2024 amounted to exchange gain of \$10,986 thousand and loss of \$10,339 thousand, respectively.

#### Cash flow and fair value interest rate risk

- The Group's interest rate risk arises from short-term borrowings and long-term borrowings. Borrowings issued at variable rates expose the Group to cash flow interest rate risk which is partially offset by cash and cash equivalents held at variable rates. Borrowings issued at fixed rates expose the Group to fair value interest rate risk.

ii. For the three-month periods ended March 31, 2025 and 2024, if the interest rate had been 25 basis point higher/lower, post-tax profit would have decreased/increased by \$1,321 thousand and \$1,539 thousand, respectively.

(b) Credit risk

- i. Credit risk refers to the risk of financial loss to the Group arising from default by the clients or counterparties of financial instruments on the contract obligations. The main factor is that counterparties could not repay in full the accounts receivable based on the agreed terms and financial assets at amortised cost.
- ii. The Group's cash and cash equivalents are deposited in financial institutions with optimal credit quality. The Group manages their credit risk taking into consideration the entire group's concern. In order to prevent excessive concentration and to disperse credit risk, the Group manages the deposit ratio in each financial institution, and the credit quality of banks and financial institutions the Group trades with is optimal. According to the Group's credit policy, each local entity in the Group is responsible for managing and analysing the credit risk for each of their new clients before payment and delivery terms and conditions are offered. Internal risk control assesses the credit quality of the customers, taking into account their financial position, past experience and other factors. The Group screens potential transaction counterparties based on their credit history, and only enters into transactions with counterparties that reach a certain level of credit quality; hence, there is no significant credit risk.
- iii. The Group adopts the assumptions under IFRS 9 to assess whether there has been a significant increase in credit risk on that instrument since initial recognition: If the contract payments were past due over 30 days based on the terms, there has been a significant increase in credit risk on that instrument since initial recognition, the default occurs when the contract payments are past due over 90 days.
- iv. The Group applies the simplified approach using a provision matrix to estimate the expected credit loss of accounts receivable, and takes into consideration the past default records and current financial position of the customer, economic condition of the industry in which the customer operates. As the Group's historical credit loss experience does not show significantly different loss patterns for different customer segments, the provision matrix uses past due days of accounts receivable to determine expected loss rates and is not further distinguished according to the Group's different customer base.
- v. The Group wrote-off the financial assets, which cannot be reasonably expected to be recovered, after initiating recourse procedures. However, the Group will continue executing the recourse procedures to secure the Group's rights.

vi. The Group used the forecast ability to adjust historical and timely information to assess the default possibility of receivables (including notes receivable, accounts receivable and contract assets). The Group first assesses and provides impairment loss for the receivables which have objective evidence to indicate that the receivables may not be recovered, and remaining receivables use historical and timely information to assess the default possibility, and taking into consideration the forecastability, in order to assess the default possibility of receivables. As of March 31, 2025, December 31, 2024 and March 31, 2024, the loss rate methodology is as follows:

March 31, 2025	Expected loss rate	Total book value	Loss allowance
Not past due	0%	\$ 490,477	\$ 18
Within 30 days	0%	-	-
31 to 90 days	0%	25,514	-
91 to 120 days	0%	3,730	-
Individual assessment	100%	<u>393,708</u>	<u>393,708</u>
		<u>\$ 913,429</u>	<u>\$ 393,726</u>

December 31, 2024	Expected loss rate	Total book value	Loss allowance
Not past due	0%	\$ 456,184	\$ 22
Within 30 days	0%	62,925	-
31 to 90 days	0%	3,652	-
Individual assessment	100%	<u>393,708</u>	<u>393,708</u>
		<u>\$ 916,469</u>	<u>\$ 393,730</u>

March 31, 2024	Expected loss rate	Total book value	Loss allowance
Not past due	0%	\$ 617,934	\$ 8
31 to 90 days	0%	1,134	-
91 to 180 days	0%	117,905	-
Individual assessment	100%	<u>393,708</u>	<u>393,708</u>
		<u>\$ 1,130,681</u>	<u>\$ 393,716</u>

vii. Movements in relation to the Group applying the simplified approach to provide loss allowance for accounts receivable are as follows:

	2025		2024	
	Accounts receivable	Other receivables	Accounts receivable	Other receivables
At January 1	\$ 393,730	\$ 4,986	\$ 393,876	\$ 4,986
Reversal of impairment	( 4)	-	( 160)	-
At March 31	<u>\$ 393,726</u>	<u>\$ 4,986</u>	<u>\$ 393,716</u>	<u>\$ 4,986</u>

viii. The Group used the forecast ability of economic forecasting announced by the Directorate General of Budget, Accounting and Statistics of the Executive Yuan to adjust historical and timely information to assess the default possibility of debt instruments. As of March 31, 2025, December 31, 2024 and March 31, 2024, in order to estimate expected credit losses.

ix. For investments in debt instruments at amortised cost and at fair value through other comprehensive income, the credit rating levels are presented below:

March 31, 2025				
Lifetime				
Significant				
	12 months	Impairment		
	credit risk	of credit		Total
Financial assets at amortised cost	<u>\$ 216,424</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 216,424</u>

  

December 31, 2024				
Lifetime				
Significant				
	12 months	Impairment		
	credit risk	of credit		Total
Financial assets at amortised cost	<u>\$ 132,524</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 132,524</u>

  

March 31, 2024				
Lifetime				
Significant				
	12 months	Impairment		
	credit risk	of credit		Total
Financial assets at amortised cost	<u>\$ 115,466</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 115,466</u>

(c) Liquidity risk

- i. Group treasury monitors rolling forecasts of the Group's liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn committed borrowing facilities, at all times so that the Group does not breach borrowing limits or covenants on any of its borrowing facilities.
- ii. Group treasury invests surplus cash in interest bearing current accounts, time deposits and marketable securities, choosing instruments with appropriate maturities or sufficient liquidity to provide sufficient head-room as determined by the above-mentioned forecasts.
- iii. The Group has undrawn borrowing facilities are as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Floating rate			
Expiring beyond one year	<u>\$ 1,729,071</u>	<u>\$ 1,945,892</u>	<u>\$ 2,062,000</u>

iv. The table below analyses the Group's non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

March 31, 2025

	Between 3				Total
	Less than 3 months	months and 1 year	Between 1 and 3 years	Over 3 years	
Short-term borrowings	\$ 382,094	\$ 20,088	\$ -	\$ -	\$ 402,182
Accounts payable	42,659	-	-	-	42,659
Other payables	168,223	-	-	-	168,223
Long-term borrowings (Note)	444,559	114,553	1,055,031	875,020	2,489,163
Lease liabilities (Note)	4,342	16,470	42,875	12,249	75,936

Note: including current portion.

December 31, 2024

	Between 3				Total
	Less than 3 months	months and 1 year	Between 1 and 3 years	Over 3 years	
Short-term borrowings	\$ 403,151	\$ 100,313	\$ -	\$ -	\$ 503,464
Accounts payable	31,190	-	-	-	31,190
Other payables	254,993	-	-	-	254,993
Long-term borrowings (Note)	158,226	211,612	1,063,548	757,550	2,190,936
Lease liabilities (Note)	7,256	12,184	28,818	25,826	74,084

Note: including current portion.

March 31, 2024

	Between 3				Total
	Less than 3 months	months and 1 year	Between 1 and 3 years	Over 3 years	
Short-term borrowings	\$ 503,183	\$ 40,082	\$ -	\$ -	\$ 543,265
Notes payable	2,788	-	-	-	2,788
Accounts payable	68,308	-	-	-	68,308
Other payables	203,167	-	-	-	203,167
Long-term borrowings (Note)	596,434	119,495	1,153,948	875,838	2,745,715
Lease liabilities (Note)	4,351	13,533	29,732	19,443	67,059

Note: Including current portion.

(3) Fair value information

A. The different levels that the inputs to valuation techniques are used to measure fair value of financial and non-financial instruments have been defined as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. A market is regarded as active where a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3: Unobservable inputs for the asset or liability. The fair value of the Group's investment in equity investment without active market is included in Level 3.

B. Financial instruments not measured at fair value

The carrying amounts of cash and cash equivalents, financial assets at amortised cost, notes receivable, accounts receivable, other receivables, refundable deposits, short-term borrowings, accounts payable, other payables, lease liabilities and long-term borrowings (including current portion) are approximate to their fair values.

C. The related information of financial and non-financial instruments measured at fair value by level on the basis of the nature, characteristics and risks of the assets and liabilities are as follows:

(a) The related information of nature of the assets and liabilities is as follows:

	March 31, 2025	Level 1	Level 2	Level 3	Total
Assets					
<u>Recurring fair value measurements</u>					
Financial assets at fair value through other comprehensive income					
- Equity securities	\$ -	\$ -	\$ 101,301	\$ 101,301	
	December 31, 2024	Level 1	Level 2	Level 3	Total
Assets					
<u>Recurring fair value measurements</u>					
Financial assets at fair value through other comprehensive income					
- Equity securities	\$ -	\$ -	\$ 109,663	\$ 109,663	
	March 31, 2024	Level 1	Level 2	Level 3	Total
Assets					
<u>Recurring fair value measurements</u>					
Financial assets at fair value through other comprehensive income					
- Equity securities	\$ -	\$ -	\$ 118,489	\$ 118,489	

(b) The methods and assumptions the Group used to measure fair value are as follows:

The fair value of financial instruments without active market is measured by using valuation techniques or by reference to counterparty quotes. The fair value of financial instruments measured by using valuation techniques refers to current fair value of instruments with similar terms and characteristics in substance, discounted cash flow method or other valuation methods.

D. The following chart is the movement of Level 3 for the three-month periods ended March 31, 2025 and 2024:

	Equity securities	
	2025	2024
At January 1	\$ 109,663	\$ 105,860
Gains recognised in other comprehensive income	( 8,362)	12,629
At March 31	\$ 101,301	\$ 118,489

E. For the three-month periods ended March 31, 2025 and 2024, there was no transfer into or out from Level 3.

F. Treasury department is in charge of valuation procedures for fair value measurements being categorised within Level 3, which is to verify independent fair value of financial instruments. Such assessment is to ensure the valuation results are reasonable by applying independent information to make results close to current market conditions, confirming the source of information is independent, reliable and in line with other resources and represented as the exercisable price, and frequently calibrating valuation model, updating inputs used to the valuation model and making any other necessary adjustments to the fair value.

G. The following is the qualitative information of significant unobservable inputs and sensitivity analysis of changes in significant unobservable inputs to valuation model used in Level 3 fair value measurement:

	Fair value at March 31, 2025	Valuation technique	Significant unobservable input	(weighted average)	Relationship of inputs to fair value
Non-derivative equity instrument:					
Unlisted shares	\$ 101,301	Market comparable companies	Liquidity premium	20.00%	The higher the multiple, the higher the fair value.

	Fair value at December 31, 2024	Valuation technique	Significant unobservable input	(weighted average)	Relationship of inputs to fair value
Non-derivative equity instrument:					
Unlisted shares	\$ 109,663	Market comparable companies	Liquidity premium	20.00%	The higher the multiple, the higher the fair value.
Non-derivative equity instrument:					
Unlisted shares	\$ 118,341	Market comparable companies	Liquidity premium	20.00%	The higher the multiple, the higher the fair value.
Unlisted shares	148	Net asset	Not applicable	-	Not applicable

H. The Group has carefully assessed the valuation models and assumptions used to measure fair value. However, use of different valuation models or assumptions may result in different measurements. The following is the effect of profit or loss or of other comprehensive income from financial assets and liabilities categorised within Level 3 if the inputs used to valuation models have changed:

	March 31, 2025					
	Recognised in profit or loss		Recognised in other comprehensive income			
	Favourable	Unfavourable	Favourable	Unfavourable		
	Input	Change	change	change	change	change
Financial assets						
Equity instrument	Liquidity premium	±10%	\$ -	\$ -	\$ 12,695	(\$ 12,695)

		December 31, 2024			
		Recognised in profit or loss		Recognised in other comprehensive income	
		Favourable	Unfavourable	Favourable	Unfavourable
		Input	Change	change	change
Financial assets					
Equity instrument	Liquidity premium	±10%	\$ _____ -	\$ _____ -	\$ 13,653 (\$ 13,653)
		March 31, 2024			
		Recognised in profit or loss		Recognised in other comprehensive income	
		Favourable	Unfavourable	Favourable	Unfavourable
		Input	Change	change	change
Financial assets					
Equity instrument	Liquidity premium	±10%	\$ _____ -	\$ _____ -	\$ 14,785 (\$ 13,203)

### 13. SUPPLEMENTARY DISCLOSURES

#### (1) Significant transactions information

- A. Loans to others: None.
- B. Provision of endorsements and guarantees to others: None.
- C. Holding of marketable securities at the end of the period (not including subsidiaries, associates and joint ventures): Please refer to table 1.
- D. Purchases or sales of goods from or to related parties reaching NT\$100 million or 20% of paid-in capital or more: None.
- E. Receivables from related parties reaching NT\$100 million or 20% of paid-in capital or more: None.
- F. Significant inter-company transactions during the reporting periods: None.

#### (2) Information on investees

Names, locations and other information of investee companies (not including investees in Mainland China): Please refer to table 2.

#### (3) Information on investments in Mainland China

- A. Basic information: Please refer to table 3.
- B. Significant transactions, either directly or indirectly through a third area, with investee companies in the Mainland Area: None.

## 14. SEGMENT INFORMATION

### (1) General information

Management has determined the reportable operating segments based on the reports reviewed by the chief operating decision-maker that are used to make strategic decisions. The Group mainly engages in the manufacture and trade of vaccines and modern medicine products, and the Group is divided into two segments according to the business nature of each department.

### (2) Segment information

The segment information provided to the chief operating decision-maker for the reportable segments is as follows:

	Adimmune Corporation	Enimmune Corporation	Total
Three-month period ended March 31, 2025			
Revenue from external customers	\$ 60,317	\$ 11,787	\$ 72,104
Inter-segment revenue	36,248	-	36,248
Total revenue	<u>\$ 96,565</u>	<u>\$ 11,787</u>	<u>\$ 108,352</u>
Segment loss	<u>(\$ 190,839)</u>	<u>(\$ 61,688)</u>	<u>(\$ 252,527)</u>

	Adimmune Corporation	Enimmune Corporation	Total
Three-month period ended March 31, 2024			
Revenue from external customers	\$ 40,155	\$ 3,723	\$ 43,878
Inter-segment revenue	-	-	-
Total revenue	<u>\$ 40,155</u>	<u>\$ 3,723</u>	<u>\$ 43,878</u>
Segment loss	<u>(\$ 166,826)</u>	<u>(\$ 28,049)</u>	<u>(\$ 194,875)</u>

### (3) Reconciliation for segment income (loss)

A. A reconciliation of the adjusted revenue and the continuing operations' revenue is provided as follows:

	Three-month period March 31, 2025	Three-month period March 31, 2024
Adjusted revenue of reportable segments (Total)	\$ 108,352	\$ 43,878
Elimination of segment income (loss)	<u>(\$ 36,248)</u>	<u>-</u>
Reportable operating department adjusted income (i.e. consolidated operating total income)	<u>\$ 72,104</u>	<u>\$ 43,878</u>

B. A reconciliation of reportable segment loss to the loss before tax from continuing operations for the three-month periods ended March 31, 2025 and 2024 is provided as follows:

	Three-month period March 31, 2025	Three-month period March 31, 2024
Reportable segment loss	(\$ 252,527)	(\$ 194,875)
Other segment loss	( 2,861)	( 5,837)
Total	( 255,388)	( 200,712)
Elimination of segment (loss) income	-	-
Loss before tax from continuing operations	(\$ 255,388)	(\$ 200,712)

(Remainder of page intentionally left blank)

Adimmune Corporation and subsidiaries  
 Holding of marketable securities at the end of the period (not including subsidiaries, associates and joint ventures)  
 March 31, 2025

Table 1

Expressed in thousands of NTD  
 (Except as otherwise indicated)

Securities held by	Marketable securities	Relationship with the securities issuer	General ledger account	As of March 31, 2025				Footnote
				Number of shares	Book value	Ownership (%)	Fair value	
Adimmune Corporation	Taiwan Biotech Co., Ltd.	-	Financial assets at fair value through other comprehensive income - non-current valuation adjustments	4,390,162	\$ 61,129	1.48	\$ <u>101,301</u>	-

Adimmune Corporation and subsidiaries  
Information on investees(not including investees in Mainland China)  
Three-month period ended March 31, 2025

Table 2

Expressed in thousands of NTD  
(Except as otherwise indicated)

Investor	Investee	Location	Main business activities	Initial investment amount		Shares held as at March 31, 2025			Investment loss		
				Balance		Number of shares	Ownership (%)	Book value	Net profit (loss) recognised by the investee for the three-month period ended March 31, 2025	(\$)	Company for the three-month period ended March 31, 2025
				Balance as at March 31, 2025	as at December 31, 2024						
Adimmune Corporation	Enimmune Corporation	Taiwan	Bio-technology	\$ 684,518	\$ 684,518	36,254,701	50.26	\$ 34,376	(\$ 61,817)	(\$ 31,070)	Note 1
Adimmune Corporation	Global Commonwealth Life Science (Holdings) Limited	Hong Kong	Investment	-	-	2	100.00	-	-	-	Notes 1 & 2
Adimmune Corporation	Adimmune B.V.	Netherland	Investment	-	-	-	100.00	-	-	-	Note 1
Adimmune Corporation	Eggs Corporation	Taiwan	Animal Husbandry	65,000	65,000	6,500,000	100.00	21,337	( 1,344)	( 1,344)	Note 1
Eggs Corporation	Animmune Corporation	Taiwan	Bio-technology	51,732	51,732	3,636,585	51.22	14,799	( 2,625)	( 1,344)	Note 3
Enimmune Corporation	Enimmune-RMT Biotech PTE. LTD.	Singapore	Bio-technology	162,910	162,910	55,000,000	55.00	14,601	( 236)	( 130)	Note 3

Note 1: The Company's subsidiary.

Note 2: Initial investment was NT\$8 (in dollars).

Note 3: It's the Company's second-tier subsidiary.

Adimmune Corporation and subsidiaries  
Information on investments in Mainland China  
Three-month period ended March 31, 2025

Table 3

Expressed in thousands of NTD  
(Except as otherwise indicated)

Investee in Mainland China	Main business activities	Paid-in capital	Investment method ( Note 1 )	Amount remitted from Taiwan to Mainland China/		Accumulated amount of remittance from Taiwan to Mainland China as of January 1, 2025	Remitted to Mainland China	Remitted back to Taiwan	Mainland China as of March 31, 2025	Net income of investee as of March 31, 2025	Ownership of remittance from Taiwan to Mainland China as of March 31, 2025	Company for the three-month period ended March 31, 2025 (direct or indirect)	Investment income (loss) recognised by the Company for the three-month period ended March 31, 2025 (Note 2)	Book value of Mainland China investments in the Company as of March 31, 2025	Accumulated amount of investment remitted back to Taiwan as of March 31, 2025	Footnote
				31, 2025	31, 2025											
Adimmune Co., Ltd. Nanjing, China	Business sales & acquisition	\$ -	1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	100.00	\$ -	\$ -	\$ -	\$ -	Notes 2 & 3

Note 1: Investment methods are classified into the following three categories:

- (1) Directly invest in a company in Mainland China.
- (2) Through investing in an existing company in the third area, which then invested in the investee in Mainland China.
- (3) Others

Note 2: The company was approved for business registration by the competent authority on August 10, 2016. As of March 31, 2025, the company still has not yet initiated its operation, thus, no related investment profit or loss.

Note 3: The numbers in this table are expressed in New Taiwan Dollars.

Company name	2025	Investment amount	Ceiling on investments in Mainland China
		approved by the Department of Investment of Mainland China as of March 31, 2025	approved by the Department of Investment of Mainland China as of March 31, 2025
Adimmune Co., Ltd. Nanjing, China	\$ -	\$ 10,000	\$ 3,180,119

Note: Calculated in accordance with the limits set in the "Principles for the Review of Investment or Technical Cooperation in Mainland China" issued by the Ministry of Economic Affairs (60% of the net value).